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INTRODUCTION 
 
This PhD thesis focuses the development and characterization of all 
physicochemical aspects of a new controlled release technology for two 
active pharmaceutical ingredient principle (Clotrimazole and Amikacin 
Sulfate) using ordered mesoporous silica until the introduction onto the 
market.  
The first chapter comprehends the characterization of different OMS 
synthesized and commercially available; the study of different 
incorporation techniques based on hydrophilicity/hydrophobicity of API; 
the characterization of the new impregnated OMS. 
Chapter 2 is oriented on the interaction details of API on silica surfaces. 
A closer look is given to the big questions of OMS-drug phenomena: 
mobility, solubility, bioavailability, etc. 
Chapter 3 highlight the differences between OMS and the spatial 
assembly of drug inside the mesoporous channels. 
Chapter 4 describes the development of the new CRT for AKS describing 
all the main aspect of the innovative semisolid formulation. In-vitro and 
ex-vivo release test has been produced and characterized, revealing the 
functionality of the OMS reservoir effect. 
In chapter 5 the same DDS have been developed for CTZ. Both the 
DDS have been compared with commercially available creams.  
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ORDERED MESOPOROUS SILICA AS DRUG DELIVERY SYSTEM: 
STATE OF THE ART 
 
ABSTRACT 
Drug delivery (DD) is the method or process of administering a pharmaceutical 
compound to achieve a therapeutic effect in humans or animals. For this 
purpose, several drug delivery systems (DDSs) have been formulated. These 
include liposomes, proliposomes, microspheres, gels, prodrugs, cyclodextrins, 
among others. Similar developments with other compounds have produced a 
plethora of new devices, concepts and techniques that together have been 
termed controlled-release technology (CRT). Amorphous silica plays a key role 
due to its favourable characteristics, such as high specific surface, 
biocompatibility, etc. In this chapter, starting from an overview on DDSs, the 
discussion will be focused on ordered mesoporous silica (OMS). Topics of this 
part will be the applications, objects and fields of use of OMS. Numerous 
questions will be open and answered regarding the main issues of OMS 
literature: firstly, the amorphization of the Active Pharmaceutical Ingredient 
(API); secondly, the different types of incorporations; thirdly, the requirement 
of DDS for low soluble API and, lastly, the description of a new CRT.  
 
DRUG DELIVERY SYSTEMS 
A drug delivery system (DDS) is defined as a formulation or a device that 
enables the introduction of a therapeutic substance in the body. It 
improves efficacy and safety by controlling the rate, time and place of 
release. This process includes the transport of a pharmaceutical 
compound in the body with the aim of achieving safely a desired 
therapeutic effect at the area where it is needed.[1] Any DDS comprises a 
drug formulation, a medical device or dosage form (to carry the drug 
inside the body) and a mechanism for the release. These systems have 
several criteria, ranging from ease of delivery to effectiveness of the 
drugs. Conventional drug delivery (DD) involves the preparation of the 
drug into a suitable form, such as a compressed tablet for oral 
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administration or a solution for intravenous administration. These dosage 
forms have been found to have serious limitations in terms of higher 
dosage requirement, lower effectiveness, toxicity and adverse side 
effects.[2] This is the case of many medications, which have unacceptable 
side effects due to the drug interacting with parts of the body that are not 
the target. Side effects limit the ability to design optimal medications for 
many diseases, such as cancer, neurodegenerative and infectious 
diseases.[3] It is also important to consider the way in which a drug is 
metabolized by the body. For instance, some Active Pharmaceutical 
Ingredient (API) are destroyed in the intestinal tract, therefore they cannot 
be introduced orally to the body. Others may be dangerous in large 
amounts, which means that for patient safety it should be used a time-
release method to deliver the drug.[2] In addition, drug dosage must be 
carefully calculated so that the body can use the drug. This requires a 
DDS which allows for precise dosing.[2] Hence, it is necessary to develop 
suitable dosage forms or controlled DDS to allow the effective, safe and 
reliable application of the pharmaceutical compound to the patient.[4] Such 
systems are being developed to overcome the limitations of conventional 
dosage forms and offer many advantages, which include:[5] 
- Improved efficiency by preventing peak-valley fluctuations  
- Increased convenience  
- Decreased toxicity  
- Decreased side effects  
- Decreased dosage frequency  
- Shorter hospitalizations  
- Lower healthcare costs (both short and long term)  
- Viable treatments for previously incurable diseases  
- Potential for prophylactic applications  
- Site specific delivery  
- Better patient compliance 
10 
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Several studies have shown that the benefits aforementioned can be 
achieved by correct timing of drug administration and controlled kinetics 
of drug release. Thus, controlled drug release regulates the rate, the 
location and aims at optimizing drug efficiency while simultaneously 
reducing adverse collateral effects.[2,5–9] 
 
DRUG RELEASE PROFILES 
The DDS employed plays a vital role in controlling the pharmacokinetic 
effect of the drug. An optimal DDS ensures that the active drug is available 
at the site of action for the correct time and duration. The drug 
concentration at the appropriate site should be above a minimal effective 
concentration (MEC) and below a minimal toxic concentration (MTC). This 
concentration interval is known as the therapeutic range (Figure I.1). 
Dosage forms can be differentiated according to the way the drug is 
released.  
The immediate release is probably the most used. The drug is released 
immediately after administration. These forms usually release the drug in 
a single action following a first order kinetics profile. In other words, the 
drug is released initially very quickly and then passes through the mucosal 
membrane into the body, reaching the highest plasma level in a 
comparatively short time. Once taken into the body, the drug is distributed 
throughout the body and elimination by metabolism and excretion occurs. 
This elimination process also follows a first order kinetics.  
The modified release of API can occur in three different ways: delayed, 
extended and pulsed release. In the first case, the API release takes place 
sometime later the initial administration, after which the release is 
immediate. The second one is when the drug release occurs for a 
prolonged period after ingestion. This allows a reduction in dosing 
frequency compared to a drug presented as a conventional dosage form. 
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Figure I.1: Example of API concentration with zero order release (a) and 
pulsed administrations (b). 
For immediate release dosage forms the time interval in which the plasma 
concentration reach the drug therapeutic range can be quite short.[10,11] 
Therefore, frequent dosing or pulsed release, with its associated 
compliance problems, is required. As a consequence, there is a 
considerable fluctuation in drug concentration level, which often is out of 
the therapeutic range.[4] This is especially an issue in chronic diseases 
when patients need to take the medication for prolonged periods (Figure 
I.1.b).  
Extended release can be achieved using a sustained or a controlled 
delivery dosage forms. Sustained release systems maintain the rate of 
drug release over a sustained period (Figure I.1.a). They achieve this 
mostly by the use of suitable polymers. On the other hand, controlled 
release systems also offer a sustained release profile but they are 
designed to lead to predictably constant plasma concentrations. This 
means that they are actually controlling the drug concentration in the 
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body, not just the release of the drug from the dosage form, as is the case 
in a sustained release system. 
 
DRUG CARRIERS 
Every pharmaceutical compound contains an API, which has a direct 
effect in the diagnosis, treatment or prevention of diseases. It is important 
to realise that the API is just one part of the medicine and it cannot be 
administered to the patient on its own. Therefore, it is necessary to 
formulate the drug into a dosage system containing drug carriers, which 
are forms that serve as mechanisms to improve the delivery and the 
effectiveness of drugs. They can be attached to drug molecules for 
targeted delivery, increased efficiency or controlled release. Many of 
these can also act as buffers to reduce the toxic effects of medications. 
These compounds can also change the way the drug acts in the body.[12,13] 
Drug carriers are used in controlled release technology (CRT) to prolong 
in-vivo actions, decrease drug metabolism, reduce drug toxicity and 
determine where the drug travels and how it behaves when it gets 
there.[12] These include synthetic and natural compounds from a variety of 
sources, ranging from lipids to nanoparticles. Some of the more common 
drug carrier systems are reported in Figure I.2.  
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Figure I.2: Liposomes (I): containers made of a lipid bilayer; their limitation is 
the extremely high fragility of the liposomal structure and the low transport 
capacity of non-soluble drugs. Microspheres (II-III): synthetic materials, such as 
ceramics or polymers, or from natural materials, such as albumin. Dendrimers 
(IV): repetitively branched molecules; their properties are dominated by the 
functional groups on the molecular surface. Soluble polymers (V): hollow 
particles that hold drugs; drugs are loaded into the core hydrophobic block 
(yellow); the crosslinking block (green) provides stability to the micelle by 
forming pH reversible bonds that allow for triggered drug release; the grey block 
gives the micelle aqueous solubility and stealth. Conjugated proteins (VI).[14]  
 
ORDERED MESOPOROUS SILICA 
Among all the CRT, ordered mesoporous silica (OMS) are a particular 
case of the previous system. Silicon dioxide (SiO2) is one of the most 
abundant oxide materials in the Earth’s crust. SiO2 is the essential 
components of all silicate materials: crystalline and amorphous. All 
silicates are constituted by the SiO4 tetrahedron (Figure I.3.I). The low 
energy process of change the siloxane bridge (Si-O-Si) allow the 
formation of infinite polymorphisms.[15]  
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Figure I.3: The SiO44- tetrahedron (I); O-Si-O angle: 109°; Si-O-Si angle: 130°-
180°. Phase diagrams of silica (II); most of this crystalline phase are not 
reversible. 
OMS are amorphous inorganic materials synthesized in the presence of 
surfactants as templates for the polycondensation of silicic species. 
Synthesis conditions such as source of silica, type of surfactant, ionic 
strength, pH and composition of the reaction mixture, temperature and 
duration of synthesis determine the characteristics of the porous structure 
and the macroscopic morphology.[16,17]  
A wide variety of ionic and non-ionic surfactants has been used for 
obtaining materials with different porous and morphological 
characteristics. The pore sizes of these materials are always very 
homogeneous ranging from 2 to 100 nm. The huge surface area which 
can easily reach values of 1000 m2·g-1 and the wide void volume (1 cm3·g-
1) delineate the ability of these materials as CRT. In addition, their thermal, 
chemical, mechanical and pH stability defines its superiority to the organic 
counterpart.[18–21] 
Table I.1: Brief summary of the main silicas used.  
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Name MCM-41 MSU-H SBA-15 KIT-6 Syloid 
Surfactant C16TABr P123 None 
pH >11 ≈7 <2 
Structure 
  
Disordered 
P6mmm Ia3d 
 
In 1992 a new family of OMS was reported as MCM-X (Mobil Crystalline 
of Materials). They are synthesized by using alkyl ammonium surfactants 
(i.e. Hexadecyltrimethylammonium bromide (C16TABr)) and tetraethyl 
orthosilicate (TEOS) or sodium silicate in basic condition. Their pore size 
and wall thickness are between 4 to 2 nm. By varying the synthesis 
conditions, different structures of the mesophase can be obtained. For 
instance: hexagonal phase (MCM-41), cubic phase (MCM-48) and 
lamellar phase (MCM-50).[22]  
The first OMS synthesized with non-ionic triblock polymers were reported 
by the Santa Barbara centre (Santa Barbara Amorphous).[23] As for MCM-
41, selecting the right surfactant and concentration different structure can 
be obtained. For instance, Pluronic P-123, 
HO(CH2CH2O)20(CH2CH(CH3)O)70(CH2CH2O)20H, is used mainly for the  
silica hexagonal structure (p6mmm); while, Pluronic F-127 for the cubic 
ia3d structure. The main characteristics of surfactants are:  
 Chain hydrophilicity-hydrophobicity 
 Head characteristic:  
o Anionic 
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o Cationic 
o Amphoteric 
o Non-ionic 
 Chain elongation 
 Chain/Head hindrance volume ratio 
These features have to be correlated with other synthesis conditions: 
 Temperature 
 pH 
 Concentrations 
 Co-solvents 
 Co-surfactant 
 Silica source 
Other families of OMS are Michigan State University (MSU), Korea 
Advanced Institute of Science and Technology (KIT).  
After the polycondensation, an hydrothermal treatment can be executed 
with the aim of enlarge and modify the pore structure and 
connectivity.[21,24] Subsequently, there is the removal of surfactant through 
filtration or extraction and calcination. 
Surface silanols (SiOH) represent the last characteristic besides highly 
organized porosity, SSA, pore volume, chemical stability, etc. Their 
content depends on the way the surfactant is removed. It can be 
modulated by post synthesis treatments. They are generated as 
stabilization of the silica surface. The presence of SiOH on the surface 
promotes the adsorption of molecules (from water to proteins) through 
hydrogen bonding (H-bond).[25]  
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Figure I.4: The surface isolated SiOH (I), H-bonded (II) and geminal (III).  
Furthermore, the presence of geminal and single SiOH allows the 
chemical modification grafting different functionalities through covalent 
linkages. For instance, they can react with alkylchlorosilanes in order to 
obtain an hydrophobic surface.[26] 
 
OMS FOR DRUG DELIVERY 
Due to these outstanding features, OMS are excellent candidates in 
biomedical systems as local drug delivery systems and bone tissue 
regeneration.[13,27–32] For controlled release applications, it has been 
shown that silica is able to store and gradually release therapeutically 
relevant drugs. Furthermore, silica is used to enhance the biocompatibility 
of several DDS, such as magnetic nanoparticles, biopolymers and 
micelles.[27] Vallet-Regi et al. were the first to explore the drug release 
properties of OMS using ibuprofen. To incorporate API they dissolved it 
in hexane, obtaining an incorporated quantity of 30% by mass.[33] They 
also have demonstrated the release of erythromycin and 
alendronate.[34,35] Other controlled release systems have shown the 
delivery of API such as vancomycin and adenosine triphosphate, 
fluorescein, β-oestradiol, cholestame and calceine, camptothecin.[31,36–39]  
OMS also show ability in the dissolution of poorly water-soluble drugs. An 
insufficient dissolution of hydrophobic drugs in the gastrointestinal fluids 
strongly limits the oral bioavailability. Mellaerts et al. loaded itraconazole 
on SBA-15, an antimycoticum known for its poor aqueous solubility. 
Gastrointestinal dissolution tests produced a supersaturated solution 
giving rise to enhanced trans epithelial intestinal transport.[40] Ambrogi et 
al. using carbamazepine into MCM-41 have verified a remarkable 
increase of dissolution rates.[41] This have evidenced that OMS is a 
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promising carrier to achieve enhanced oral bioavailability for drugs with 
extremely low water solubility.  
At the state of the art, the explanation of these phenomena should be a 
consequence of drug amorphization inside OMS. Numerous works have 
demonstrated drug amorphization inside OMS just by mechanical mixing, 
without any other energy supplement. These could demonstrate that the 
most stable condition of drug inside silica mesopores is an amorphous 
state. Indeed, NMR studies have evidenced high mobility of drug inside 
OMS at ambient temperature and pointed out weak interactions.[42,43] 
These arguments will be discussed in chapter 2. 
 
DRUG LOADING STRATEGIES 
Drug loading into a host material can be performed with different 
techniques.[44]  
The solution method is probably the most widely used drug loading 
process. In this method, the drug is dissolved in a suitable solvent and the 
porous material is dipped in this solution. The drug molecules are 
absorbed on the pore walls. The solution method last from one to several 
hours, after which OMS is separated from the solution by filtration or 
centrifugation. In conclusion, the particles are dried by removing the 
remaining solvent.[45] If the drug concentration near to the adsorbent 
surface exceeds the saturation concentration, e.g. during the drying step, 
the drug may start to crystallize on the external adsorbent surface. Since 
this crystalline surface fraction may have different dissolution properties 
than the amorphous solids inside the pores, its formation is not 
favourable. If crystalline solids are formed on the surface, they can be 
removed by washing the loaded particles. Unfortunately, the washing 
process is difficult to control.[46] Solution loading is simple to perform and 
it gives reproducible results as the properties of the carrier are consistent. 
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High temperature is not required during the process, making it suitable for 
loading sensitive molecules. To achieve high loading degrees, relatively 
high concentrations of loading solutions have to be used. This can be 
challenging, especially with poor soluble drugs. To overcome this 
inconvenience, different solvents can be used. Among all the possibilities, 
apolar solvent are the most appropriate. Indeed, it has been demonstrated 
that water, ethanol and other polar solvents compete in the adsorption 
with the drug. In fact, due to the high interaction energy and strong H-
bonds formed with surface silanols, these molecules are strayed from 
silica surface only during degas operations. On the other hand, most 
apolar solvent are carcinogen or toxic.[8] The main disadvantage of the 
immersion method is the large proportion of the drug that is wasted in the 
filtration/centrifugation process. It is also difficult to predict the drug 
loading degree that will be achieved. 
The Incipient wetness impregnation (IWI) method consists in contacting 
the OMS with a volume of solvent equal to the silica pore volume. The 
capillary action draws the solution into the pores and the drug dissolved 
in it. The support can be dried to drive off the volatile components within 
the solution, depositing the drug on its surface. While drying, the drug 
located in the solution outside the pores is driven inside by diffusion, which 
is a much slower process. There are different methodologies 
distinguished by the volume of solvent used:[47]  
 Impregnation by soaking or with an excess of solution: excess 
liquid is eliminated by evaporation or by draining; 
 Dry or pore volume impregnation: the amounts of drug are 
introduced in the volume corresponding to the pore volume of the 
support;  
 IWI: it is a procedure similar to dry impregnation, but the volume 
of the solution is more empirically determined to correspond to that 
beyond which the support begins to look wet.  
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The main advantage of this methods is that it is easy to control the amount 
of the drug that is loaded in the carrier. Furthermore, the drug is efficiently 
loaded and the method is, therefore, suitable for expensive molecules. 
 
Figure I.5: Comparison between different incorporation process and drug 
adsorption.[48] 
Covalent grafting method is widely used for payload molecules, which can 
be loaded by attaching them covalently on the mesoporous material 
surfaces. A commonly used method is to form a peptide bond between 
the amine group of a payload molecule and a carboxylic acid linker on the 
surface of the material. The benefit of a chemical grafting is the possibility 
to control the release of the payload molecules. The release can be 
determined by cleavage of the payload molecule from the linker or erosion 
of the porous material. In chemical grafting, the drug load is controlled by 
the surface area and the density of the linker and the payload molecules. 
The maximum loading degree that can be achieved is inevitably lower 
than this that can be achieved with non-covalent adsorption methods, 
because the payload molecules cannot accommodate the whole pore 
volume. With this method, there is a risk that the payload molecule will not 
be released from the linker. Nevertheless, this method provides stronger 
chemical interactions between the drug molecule and the surface.[16]  
It is important to remember that all the methods aforementioned have an 
inherent disadvantage: the employment of organic solvents. The 
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subsequent solvent removal steps add processing complexity and 
increased cost to these processes. In addition, there are safety issues to 
be considered and appropriate environmental protection measures must 
be initiated when using organic solvents. To avoid this, other techniques 
can also be employed to load drugs onto OMS. 
In the hot melt method drug molecules are loaded from a molten phase. 
The drug is heated along with the adsorbent to a temperature above the 
melting point of the drug. A prerequisite for using this method is that both 
the adsorbent and the drug have sufficient thermal stability, which 
excludes all of the pharmaceuticals that are known to decompose upon 
melting.[46] Some drugs as ibuprofen has been successfully loaded by 
using this method. However, this method is not generally appropriate 
because it requires the molecules to withstand a temperature above their 
melting point and the viscosity must be low enough to allow the molecule 
to efficiently enter the pore structure.  
Vapour deposition is another technique. In high vacuum condition, the 
melting temperature of the drug is reduced. Consequently, it is possible 
to avoid degradation and evaporates small amount of drug that will be 
deposited in a cold region (OMS). This method allows to control the purity 
of the drug avoiding any external parameter: solvent, viscosity, solubility, 
etc. 
The physical mixing, for instance, requires only that drug and carriers are 
blended in desired proportions using spatula for some minutes. A more 
scalable process of the physical mixing is the ball milling. Indeed, during 
the process the particles are physically broken to favour the drug 
entrapment and reconstituted due to the strong interaction energy of silica 
surfaces.  
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SUPERCRITICAL CO2  
Organic solvents can be replaced with supercritical carbon dioxide. Drugs 
may also be incorporated by dissolving them in compressed high volatile 
fluids like supercritical carbon dioxide (scCO2), at temperatures and 
pressures above their critical point.[49] A supercritical fluid can be defined 
as any substance present at a temperature and pressure higher than its 
critical value, and which has a density close to or higher than its critical 
density. At the point at which the critical temperature and critical pressure 
are reached, the density of both the liquid and vapour are equal and the 
supercritical phase is obtained.  
The employment of scCO2 for drug loading offers many advantages 
compared to traditional organic solvents. This topic will be discussed in 
details in chapter 1. 
Supercritical fluids have both liquid and gas-like properties. Their liquid-
like nature enables them to act like a solvent, while their gaseous 
properties allow quick and easy diffusion through materials.[50] When the 
supercritical state is reached, properties like density, viscosity and the 
vapour–liquid equilibrium ratio become dependent on temperature at a 
certain pressure, which permits the solubility of solutes in the supercritical 
fluid to be controlled. 
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Figure I.6: Phase diagram of a CO2 showing the supercritical region and critical 
point.[50] 
At pressures and temperatures not too far from its critical point, a 
supercritical fluid has a high compressibility. Therefore, its density and its 
solvent power are easily adjustable over a wide range with a minimal 
change in temperature or pressure. This tunability may be used to control 
the solubility parameter.[50]  
The solubility parameter is a coefficient that indicates a substance 
solubilisation in a specific solvent. Materials with similar values are likely 
to be miscible, hence a solute presents a complete solubility or miscibility 
if it has a solubility parameter as equal as possible to that of the solvent. 
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Figure I.7: CO2 solubility parameter as a function of Temperature, Pressure 
and Density.[50]  
In a supercritical fluid, the solubility parameter tends to increase with the 
fluid density (at constant temperature).[50] Another advantage includes the 
reduced processing complexity, as there is no need for solvent removal 
steps associated with organic solvent usage.[51–53] Carbon dioxide is the 
most widely used supercritical fluid because it presents the advantage of 
having easily accessible critical conditions, that are a critical temperature 
close to ambient temperature (304.25 K) and a critical pressure which is 
not too high (7.39 MPa), it is inert, non-flammable and inexpensive. The 
critical temperature is close to a physiological value and so it is safe for 
heat-sensitive proteins.  
One disadvantage of using supercritical fluids, however, is that 
specialised high-pressure equipment and knowledge are required for 
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processing it. Furthermore, some interesting hydrophobic drugs, which 
cannot be impregnated by aqueous solution-suspension soaking, can be 
incorporated by this method.  
ScCO2 is used for many applications like: 
 Extraction of desired compound from other products; i.e. caffeine 
from coffee bean;[54] 
 Chromatography; 
 Cleaning; 
 Biological applications:[55,56] 
o Sterilization 
o Virus inactivation 
 Particle formation 
o Aerogels[57] 
 Polymeric processing and foams;[58] 
 Impregnation 
o Drug loading on different matrixes[59] 
In this thesis, it will be used as an incorporation process for drug inside 
OMS. This topic will be further discussed in chapter 1.  
 
TOPICAL APPLICATION 
Among all the administration routes, topical and transdermal delivery 
approaches have unique advantages:  
 In case of skin diseases, topical delivery directly carries drugs to 
the site; 
 Smaller amounts of drugs are needed to produce a therapeutic 
effect; 
 Plasma level peaking of drugs will be avoided; 
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 Increased bioavailability due to elimination of hepatic first-pass 
metabolism; 
 Greatly enhanced patient compliance by eliminating frequent 
treating. 
For these reasons and many others, currently, there are numerous topical 
and transdermal products on the market. Many formulations of low 
molecular weight drugs and macromolecules have been developed and 
some are currently under clinical trial.[60] 
At the same time a huge number of CRT have been developed for topical 
diseases, such as gels with permeation enhancers, submicron emulsion 
vehicle systems, volatile vehicle–antinucleant polymer systems, lecithin 
microemulsion gel, oleo-hydrogel systems, deoxycholate hydrogels, 
creams containing lipid nanoparticles, solid lipid nanoparticles, liposomes 
as drug carriers, etc.[61] 
Human skin has a surface area between 1.5 and 2.0 m2 for adults. The 
skin thickness varies over the body with the thinnest part of eyelids being 
less than 0.1 mm thick and the thickest on the palms, soles and upper 
back more than 5.0 mm. Not only is the skin a protective barrier against 
toxic substances, pathogens, and organisms, but it is also involved in 
many important physiological functions such as fluid homeostasis, 
thermoregulation, immune surveillance and sensory detection.[62] These 
functions are related to the skin’s complex multiple layers with each layer 
associated with highly specified cells and structures.  
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Figure I.8: A schematic image of epidermis, dermis and hypodermis structure. 
The appendages such as hair shaft and hair follicle, sweat gland, sebaceous gland, 
and arrector pili muscle are illustrated.[63] 
The permeation barrier properties of human skin are mostly attributed to 
the top layer of the epidermis, the stratum corneum. The barrier function 
is related to the unique structure in the stratum corneum layer that is 
composed of “bricks (corneocytes) and mortar (intercellular lamellar lipid 
bilayers)”.[64] 
Approaches that deliver drugs/active compounds through the skin barrier 
are referred to the topical administration (as opposed to the enteral and 
parenteral route). Passive and active skin penetration enhancement 
methods have been successfully used to improve the efficiency of either 
the topical delivery (the drugs/active compounds are delivered into skin 
strata), or transdermal delivery (drugs/active compounds are delivered 
into subcutaneous tissues and are taken up systemically into the body). 
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Topically applied therapies are promising for the treatment of skin 
diseases such as psoriasis, contact dermatitis and skin cancers, since the 
drugs are delivered directly into skin strata. 
 
A NEW CONTROLLED RELEASE TECHNOLOGY 
Despite of all the above descripted benefits of topical administration, there 
are some critical drawbacks, among which difficult accurate dose and the 
need of frequent reapplications.[11] These frequent reapplications are 
required because the post-application efficacy of traditional creams is 
limited to a period between 3 to 6 hours. In addition, recurrent treatments 
result in considerable inconvenience for the patient and inopportune 
amnesia. Moreover, many dermatologic pathologies, grouped under the 
generic name of chronic dermatitis, have a cyclic and recurring feature, 
creating complex treatment problems over the course of the patient’s life. 
What is more, pulsed administration has period of inefficacy and 
overdose, due to low/high API concentration on the skin site (Figure I.1).  
In order to tackle these issues, zero order release at constant skin 
concentration for an extended time interval is required but is utopian. 
Sustained controlled release systems aims to simulate as good as 
possible the zero order release. A new CRT comprising OMS, 
incorporated with different API, blended in a saturated solution of the 
same API is here proposed. Indeed, this semisolid formulation let to a 
sustained controlled release. After the application on the skin site, the 
dissolved API in the saturated solution explicate its function as all the 
commercial creams. Subsequently, the concentration of the dissolved API 
begins to decrease leading to the end of the cream purpose. 
Simultaneously, the API incorporated in OMS begun to dissolve. The API 
release preserves the saturated concentration inside the vehicle until the 
OMS is empty. As follows, the therapeutic concentration of API is kept 
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constant on the application site for a long and controlled time. The OMS 
incorporated with API develop a reservoir effect. 
 
Figure I.9: A schematic image of the patented application. 
This new CRT is patented at the WIPO (the global forum for intellectual 
property services, policy, information and cooperation) with numbers 
WO2012007906 A2-A3. At the European patent office as EP2593083 A2 
and on the United States territory as US20130156832 A1. 
 
DERMATOLOGICAL DISEASE 
The major challenges in the skin diseases treatment include poor 
efficiency of drug delivery into the disease site and risks of increased 
toxicity associated with approaches used to improve the drug delivery 
efficiency. 
In this thesis, two main drugs have been explored for the treatment of 
different diseases. The first is clotrimazole (CTZ), a synthetic imidazole 
derivative. It is primarily used locally in the treatment of vaginal and skin 
infections due to yeasts and dermatophytes. In vitro, it is most active 
against Candida spp., Trichophyton spp., Microsporum spp. and 
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Malazzesia furfur (Pityrosporon orbiculare). In addition, it has some in 
vitro activity against certain Gram-positive bacteria and at very high 
concentrations it has activity against Trichomonas spp. In the treatment 
of vaginal candidiasis, CTZ vaginal tablets have produced cure rates 
comparable with those of conventional nystatin vaginal tablets. CTZ 
topical preparations are generally well tolerated, but local irritation has 
required withdrawal of therapy in a few cases. The site of action of CTZ, 
like that of miconazole and the polyene antifungal agents, appears to be 
the cell membrane to which it is preferentially bound. It has been proposed 
that the mechanism of action involves an interaction with the phospholipid 
layer of cellular membranes causing alterations in membrane 
permeability. Permeability changes result in loss of essential precursors, 
metabolites and ions, thus inhibiting macromolecular synthesis. 
Absorption of CTZ through intact skin was essentially negligible in 
individuals with normal skin. The highest concentration of topically applied 
CTZ remained in the epidermis, particularly in the stratum corneum, with 
less appearing in the dermis, and very little penetrating subcutaneously. 
Consequently, topical administration avoids side effects of oral 
administration like itching, nausea, vomiting and abnormal liver activity.[65] 
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Figure I.10: Chemical structure of Clotrimazole: 1-[(2-
Chlorophenyl)(diphenyl)methyl]-1H-imidazole.[66] 
The second one, Amikacin sulfate (AKS) is an aminoglycoside antibiotic 
used to treat different types of bacterial infections. AKS works by binding 
to the bacterial 30S ribosomal subunit, causing misreading of mRNA and 
leaving the bacterium unable to synthesize proteins vital to its growth. 
AKS is most often used for treating severe, hospital-acquired infections 
with multidrug-resistant Gram-negative bacteria, such as Pseudomonas 
aeruginosa, Acinetobacter and Enterobacter. AKS can also be used to 
treat non-tubercular mycobacterial infections and tuberculosis when first-
line drugs fail to control the infection. Side effects of AKS are similar to 
those of other aminoglycosides. Kidney damage and hearing loss are the 
most important effects.  
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Figure I.11: Chemical structure of Amikacin: (2S)-4-Amino-N-[(2S,3S,4R,5S)-
5-amino-2-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-
yl]oxy-4-[(2R,3R,4S,5R,6R)-6-(aminomethyl)-3,4,5-trihydroxy-oxan-2-yl]oxy-3-
hydroxy-cyclohexyl]-2-hydroxy-butanamide.  
AKS may be administered once or twice a day but it must be given by 
intravenous or intramuscular route or via nebulization. For the treatment 
of dermatological disease, the topical route avoid the majority of side 
effects.[67] 
CTZ and AKS were chosen for the ability to be topically administrable, low 
toxicity, the number of administration during the day (2-5 dose/day) and 
their opposite characteristics. The first drug is an antifungal, the second 
one is an antibiotic; one have a long half-life, the other short; but more 
important, CTZ is hydrophobic, while AKS is hydrophilic. Indeed, the main 
incorporation strategies will be scCO2 for CTZ and IWI for AKS. 
 
AIM OF THE THESIS  
The aim of this PhD work was to develop and characterize all 
physicochemical aspects of this new CRT for CTZ and AKS using OMS 
until the introduction onto the market.  
The first part comprehends the characterization of different OMS 
synthesized and commercially available; the study of different 
incorporation techniques based on hydrophilicity/hydrophobicity of API; 
the characterization of the new impregnated OMS. 
Consequently, the work is oriented on the interaction details of API on 
silica surfaces. A closer look is given to the big questions of OMS-drug 
phenomena: mobility, solubility, bioavailability, etc. 
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Therefore, all the scCO2 incorporation parameters have been studied, 
highlighting the differences between OMS and the spatial assembly of 
drug inside the mesoporous channels. 
Thus, the patented CRT has been developed for AKS describing all the 
main aspect of the innovative semisolid formulation. In-vitro and ex-vivo 
release test has been produced and characterized, revealing the 
functionality of the OMS reservoir effect. 
Finally, the same DDS have been developed for CTZ. Both the DDS have 
been compared with commercially available creams. 
 
  
34 
 
ORDERED MESOPOROUS SILICA FOR DRUG DELIVERY IN TOPICAL APPLICATIONS 
 
ORDERED MESOPOROUS SILICA AS DRUG DELIVERY SYSTEM: 
EXPERIMENTAL 
 
MATERIALS 
 
ORDERED MESOPOROUS SILICA 
The synthesis of OMS are here reported. 
MCM-41 
Four different MCM-41 have been used during this thesis. The first one 
named MCM41-1 has been synthesized following the procedure of Jana 
et al.[68] Briefly, 25.04 g of hexadecyltrimethylammonium bromide 
(C16TMABr) was dissolved in 75.22 g of water at 323 K. Subsequently, 16 
g of 1,3,5-trimethylbenzene (TMB) was added and stirred vigorously. In 
another solution 1.8 g of H2SO4 and 1.8 g of waterglass (Na2SiO3) were 
added to 60 g of H2O. These two solutions were then mixed and stirred 
vigorously for 30 min. Then again 30 g of water was added to this mixture, 
stirring constantly. The pH of the gel was adjusted close to 10 by adding 
dilute sulfuric acid and then the resultant gel was transferred into a teflon-
lined autoclave and heated statically at 373 K for its crystallization under 
autogeneous pressure in an oven for 10 days. After crystallization, the 
solid product was recovered by filtration, washed with large amounts of 
warm deionized water and dried at 373 K and finally calcined in air at 813 
K for 6 hours.  
MCM41-2, MCM41-3 and MCM41-4 were synthesized following the 
procedure of Grun et al.[20] modified in order to change the pore size 
distribution of OMS. Briefly, n-Alkyltrimethylammonium bromides of 
different alkyl chain lengths were used as template: C16TMABr and TMB 
for MCM41-2; C16TMABr for MCM41-3; C12TMABr for MCM41-4. The 
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template was dissolved in 120 g of deionized water to yield a 0.055 mol/L 
solution, and 9.5 g of aqueous ammonia (25 % by mass, 0.14 mol) was 
added to the solution. While stirring 10 g of Tetraethoxysilane (0.05 mol) 
(TEOS) was added slowly to the surfactant solution over a period of 15min 
resulting in a gel with the following molar composition: 1 TEOS:0.152 
CnTMABr:2.8 NH3:141.2 H2O The mixture was stirred for one hour, then 
the white precipitate was filtered and washed with 100 ml of deionized 
water. After drying at 363 K for 12 h, the sample was heated to 823 K (1 
K/min) in air and kept for 5 h to remove the template. 
A fifth sample was a commercially available MCM-41 bought from ACS 
Material (MCM41-ACS). 
 
KIT-6 
Mesoporous KIT-6 silica materials were obtained following the method 
reported Kleitz et al.[69] Briefly, 9.0 g of Pluronic P123 (EO20PO70EO20, 
Sigma-Aldrich) was dissolved in 325 g of distilled water and 17.40 g of 
HCl (37%) under vigorous stirring. After complete dissolution, 9.0 g of 1-
butanol (BuOH, Aldrich, 99%) was added. The mixture was left under 
stirring at 308 K for 1h, after which 19.35 g of TEOS was added to the 
homogeneous clear solution. The synthesis is carried out in a closed 
polypropylene bottle. This mixture was left under stirring at 308 K for 24 
h, followed by an aging step, alternatively at 50, 80, 100, or 130 °C for 24 
h under static conditions (this process is referred to as hydrothermal 
treatment). The resulting solid products were then filtered and dried for 48 
h at 95 °C. For template removal, the as-synthesized silica powders were 
first shortly slurried in an ethanol-HCl mixture and subsequently calcined 
at 823 K for 2 h. The KIT-6 produced are referred in this thesis as KIT6-
50, KIT6-80, KIT6-100, KIT6-130 in order to report the hydrothermal 
temperature treatment. 
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SBA-15 
SBA-15 was synthesized according to the method described by Zhao et 
al.[23] First, 4.0 g of surfactant, Pluronic P123, were dissolved in 30 g of 
water and 120 g of 2 M hydrochloric acid solution. Then, 8.5 g of TEOS 
was added. This solution was stirred for 20 h at 308 K and then aged at 
353 K overnight, without stirring (hydrothermal treatment). Finally, the 
product was collected by filtration, washed, and air-dried at room 
temperature. Calcination was carried out at 873 K (1 K/min) for 6 h. These 
sample is named as SBA15-C in this work. 
Another sample was a commercially available SBA-15 and it was bought 
from ACS Material (SBA15-ACS). 
 
MSU-H 
OMS of MSU-H type were bought from Sigma Aldritch and kindly provided 
by Formac Pharmaceuticals (MSU-H-F) 
 
DISORDERED MESOPOROUS SILICA 
Two porous silica, with trade name Syloid AL-1 FP, were donated from 
Grace GmbH & Co. These are disordered silica synthesized without the 
use of any template but with different pore size distribution centred on 1 
and 10 nm. Consequently, they were named as Syloid-1 and Syloid-10. 
 
ACTIVE PHARMACEUTICAL INGREDIENT 
Amikacin sulfate (AKS) (MW = 781.76 g/mol) (Ph.Eur 8.2) (purity 99,8%) 
and Clotrimazole (CTZ) (MW = 344.837 g/mol) (purity 98.9%) were 
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acquired from Sigma Aldritch. They were used as such, without any 
purification procedure. 
 
CHEMICALS 
Carbon dioxide with a purity of 99.5% was supplied by SIAD. Bidistilled 
water was supplied by J.T.Baker. All the reagents required for OMS 
synthesis (C16TMABr, TMB, TEOS, etc.), 1-fluoro-2,4-dinitrobenzene 
(FDNB), 1,2-propandiol, glycerol, acetonitrile and hydroxyethyl cellulose 
(Natrosol MR) were purchased from Sigma Aldritch. Commercial 
formulation of AKS (5% by mass) and CTZ (2% by mass) were purchased 
from a community pharmacy. 
 
CHARACTERIZATION METHODS  
X-RAY DIFFRACTION 
X-Ray Diffraction (XRD) and wide angles patterns were obtained using a 
PANAlytical X’Pert Pro (Cu Kα radiation) diffractometer with a PIXcel1D 
photon detector.  
 
FOURIER TRANSFORM INFRARED SPECTROSCOPY  
For Fourier Transform InfraRed (FTIR) measurements, powders were 
pressed in self-supporting wafers and spectra were recorded at room 
temperature with a Bruker Tensor 27 spectrometer operating at 2 cm-1 
resolution. If degassing was necessary, the sample were outgassed at 
373 K for one hour (residual pressure equal to 0.1 Pa). FTIR spectrum of 
crystalline API were recorded on the powder dispersed in potassium 
bromide (KBr). FTIR spectrum of API dissolved in solution were recorded 
on a diluted carbon tetrachloride (CCl4) solution (1 g/L). 
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NITROGEN ADSORPTION  
Nitrogen adsorption isotherms were measured using a Quantachrome 
AUTOSORB-1 instrument after degassing at 373 K for 2 hours. Brauner-
Emmet-Teller (BET) specific surface areas (SSA) were calculated in the 
relative pressure range 0.04-0.1 and the pore size distribution was 
determined through the NLDFT (Non Linear Density Functional Theory) 
method, using the NLDFT equilibrium or adsorption model for cylindrical 
pores.[22] 
 
TERMOGRAVIMETRY 
TermoGravimetric (TG) analyses were carried out between 298 K and 
1523 K in air (flow rate 100 mL/min with a heating rate of 10 K/min) using 
a SETARAM 92 instrument.  
The API desorption analysis were performed using a SETARAM 92 
instrument following the procedure explained by Verevkin et al.[70] and 
Price et al.[71] Using the Clausius-Clapeyron relation, equation (1), the 
enthalpies of vaporization (∆Hvap) at the average temperature of 
investigation were obtained.  
 
𝑙𝑛 (√𝑇
𝑑𝑚
𝑑𝑡
) = 𝐴 +
∆𝐻𝑣𝑎𝑝
𝑅𝑇
                                                     (1) 
 
where dm/dt is the mass loss rate at the specified temperature; R is the 
universal gas constant and T is the temperature of the isothermal 
experiment. Subsequently, vaporization enthalpies were reported to 
298.15 K using general methods of correction, reported by Chickos et 
al.[72] (the Sidgwick’s rule):  
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∆𝐻𝑣𝑎𝑝(298.15) = ∆𝐻𝑣𝑎𝑝(𝑇) + 0.0545 (𝑇 − 298.15)                        (2) 
 
In equation (2), T is the temperature of measurement or mean 
temperature of measurement if ∆Hvap (T) has been obtained from a 
Clausius-Clapeyron treatment of vapor pressures. The experimental 
conditions used for the reliable determination of vaporization enthalpies 
of low volatile molecular compounds are following the references of 
Verevkin at al.[70] A calibration curve with phenol has been done. The 
uncertainty of temperature calibration was less than 1 K. 
 
DIFFERENTIAL SCANNING CALORIMETRY  
Differential Scanning Calorimetry (DSC) measurements were performed 
with a DSC1 STARe (Mettler Toledo) System apparatus of TA Instruments 
equipped with a low temperature probe between 298 K and 1073 K under 
nitrogen flux (flow rate 60 mL·min-1 with a heating rate of 10 K·min-1). 
 
SCANNING ELECTRON MICROSCOPY 
Field Emission Scanning Electron Microscopy (FESEM) image were 
recorded with a FESEM ZEISS MERLIN.  
 
DINAMIC LIGHT SCATTERING AND ZETA POTENTIAL  
Dinamic Light Scattering (DLS) and Zeta Potential analysis were 
performed with 90 Plus Instrument (Brookhaven) on a suspended water 
mixture of OMS after homogenization with a high shear homogenizer 
(Ultraturrax, Ika) for 5 min at maximum velocity. 
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NUCLEAR MAGNETIC RESONANCE 
Solid State Nuclear Magnetic Resonance (SSNMR) spectra were 
recorded on a Bruker Avance II 400 instrument operating at 400.23 and 
100.65 MHz for 1H and 13C nuclei, respectively. 4 mm o.d. zirconia rotors 
(sample volume of 80 µL) were employed and spun at 12 kHz for 13C 
CPMAS spectra. A ramp cross-polarization pulse sequence was used with 
contact times of 3–5ms, a 1H 90° pulse of 3.8 µs, recycle delays of 1–60 
s and 48–4096 transients. 1H MAS spectra were performed on a 2.5 mm 
probe with a spinning speed of 32 kHz. A DEPTH sequence (π /2-π-π) 
was used to suppress the probe background signal.[73,74] The 1H 90° pulse 
length was set to 2.50 πs, the recycle delays to 1-40 s and 32-64 
transients were averaged for each sample. 1H and 13C chemical shifts 
were referenced through the resonance of adamantane (1H signal at 1.87 
ppm) and hexamethylbenzene (13C methyl signal at 17.4 ppm), 
respectively. 
 
DRUG INCORPORATION METHODS 
SOLUTION 
API incorporation was performed by adsorption from solution. To this 
purpose, normally, 300 mg of API and 100 mg of OMS were introduced in 
an Erlenmeyer flask with 5 ml of solvent (water or ethanol) and maintained 
at room temperature under stirring for 24 hours. Then the powder was 
filtered and dried overnight in vacuum (residual pressure 0.1 Pa).  
 
INCIPIENT WETNESS IMPREGNATION 
The API loading was performed by Incipient Wetness Impregnation (IWI) 
procedure, based on the capillary action [47]. Typically, 1 ml of a saturated 
solution of API was added drop by drop to one gram of OMS during 
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mechanical agitation. The homogeneous wet powder obtained was 
vacuum dried for 24 hours at 0.1 Pa obtaining a dry powder. For the IWI 
water and ethanol were used as solvents. 
 
SUPERCRTICAL CO2  
For the incorporation process by means of scCO2 a homemade device 
was used. This consists in a glass cylinder of 1 cm diameter containing a 
pellet of CTZ (100 mg) and a pellet of OMS (100 mg) separated by a disc 
of filter paper, in order to prevent their contact and to separate the pellets 
after the incorporation process.  
 
Figure 1.11: Photograph of the homemade device used for the scCO2 
incorporation process. 
This device was placed inside a stainless steel vessel, which was put in 
an oven that maintained all the system at constant temperature. The 
apparatus was also equipped with a volumetric pump and a back pressure 
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regulator. A scheme of the apparatus is reported in Figure 1.12 and further 
details can be found elsewhere.[75] 
 
Figure 1.12: scCO2 apparatus details: B – CO2 tank; P1 – CO2 pump; P2 – co-
solvent pump (not used); P3 – hexane pump (not used); Vxx – valves On/Off; 
V4/V5/V12/V13 three way valves; VNR – not returning valve; R – reactor; M – Mixer; 
S – heating coils; F – oven; BPR1 – manual back pressure regulator; BPR2 – 
automatic back pressure regulator; PE – heating pad; Tx – trap; FIx – mass flow 
meter. 
The incorporation was performed in static condition. The vessel was filled 
with liquid CO2 and heated up to 373K. After the heating, additional carbon 
dioxide was pumped in the vessel to reach the final desired pressure (25.0 
MPa). The system was then maintained in the described conditions for 
several hours (from 6 to 18) to allow the drug dissolution and diffusion into 
the OMS. At the end of the incorporation process, the temperature was 
decreased to room conditions and the apparatus was depressurized.  
 
AB-INITIO AND MOLECULAR DYNAMICS SIMULATIONS 
All the calculations were performed within the Density Functional Theory 
(DFT). Concerning static calculations, the developmental version of the 
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CRYSTAL14 code29 in its massively parallel version[77] was adopted and 
the computational approach is the same of Ref.[78]. Briefly, the chosen 
functional was the Perdew, Burke, and Enzerhof GGA (Generalized 
Gradient Approximation) exchange-correlation functional (PBE),31 
including the empirical Grimme’s D2 correction,[80] to describe the 
dispersive interactions (vdW). In the following, the superscript D means 
that Grimme’s correction is included. Split valence double- (for Si atoms) 
and triple-ζ (for other atoms) Gaussian type basis sets plus polarization 
functions were used to describe the systems.[81,82] Chlorine atoms were 
represented with a 86-311G* basis set.[83] Only the atomic coordinates of 
the two more superficial layers of each silica slab in the docking 
geometries were optimized, to compensate for the reduced thickness of 
the models. Starting geometries were generated so to maximize the 
interactions between the drug and the surface. Interaction energies, per 
unit cell per adsorbate molecule (∆E), were calculated and corrected for 
the basis set superposition error (BSSE) according to the counter-poise 
methodology described in previous papers by Delle Piane et al.23,25 and 
reported in Supporting Information. 
Harmonic frequencies were calculated with CRYSTAL14 at Γ point and 
the infrared intensity for each normal mode was obtained by computing 
the dipole moment variation along the normal mode, adopting the Berry 
phase method.[85] For the simulation of the IR spectra of the different 
structures, only a fragment consisting of the most interesting chemical 
groups has been considered for constructing the Hessian matrix and will 
be defined for each case in Results and Discussion. 
Enthalpies (ΔH) of adsorption at standard temperature (298 K) were 
obtained from the vibrational partition functions, by applying the Zero 
Point Energies (ΔZPE) and thermal (ΔET) corrections to the BSSE 
corrected electronic adsorption energies (∆EC) as ∆H = ∆EC + ∆ZPE + 
∆ET. 
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Ab-initio molecular dynamics (AIMD) simulations were performed using 
the CP2K code.[86] The Quickstep technique[87] with a mixed plane wave 
and Gaussian basis set methodology (Gaussian and Plane Wave method, 
GPW) was employed to calculate the electronic structure. We used the 
PBE functional, with the Goedecker−Teter−Hutter pseudopotentials[88] 
and a triple-ζ basis set with polarization functions (TZVP)[89] augmented 
with the empirical Grimme’s D2 correction.[80] The cutoff for the plane 
wave basis was set to 400 Ry. AIMD simulations were run at 300 K in the 
NVT ensemble, using the Canonical Sampling through Velocity Rescaling 
(CSVR) thermostat.[90] A time step of 0.5 fs was chosen. All simulations 
were equilibrated at 300 K with a more stringent thermostat (time 
constant: 10 fs) for about 1 ps and then the production phase was run for 
at least 10 ps with a more relaxed thermostat (time constant: 50 fs). Since 
CP2K requires 3D periodic systems, a value of c = 35 Å was chosen to 
separate the slab replicas with enough vacuum. In all cases, only the 
superficial layer of the silica slab and the drug molecules were allowed to 
move. 
 
DRUG RELEASE 
 
RELEASE KINETICS 
The drug release kinetic of API to the saturated concentration were 
evaluated in vitro by soaking 100 mg of OMS incorporated by API (OMS-
API) in 5 ml of stirred solvent. At different time intervals, a small amount 
of solution (100 μl) was collected, diluted and analysed through UV–Vis 
spectrophotometry analysis. To assess the amount of released API a 5-
point calibration curve has been obtained.  
RESERVOIR EFFECT 
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The reservoir effect of saturated solution with OMS-API have been 
evaluated for AKS and CTZ. In a saturated solution of API a certain 
amount of OMS, impregnated with the same API, were added under 
agitation. At regular intervals (1h) a small amount of solution (between 
500-100 μl) were withdraw and substituted with the same quantity of pure 
solvent. The extracted solutions were then diluted and analysed through 
UV–Vis spectrophotometry to assess the API concentration. The addition 
of pure solvent causes a dilution of the solution and allow us to evaluate 
the reservoir effect of impregnated OMS. In order to evaluate the correct 
content of drug in the solution a 5-point calibration curves has been done 
for CTZ and AKS in the respective solvent. The coefficient of 
determination was 0.997 for CTZ and 0.995 for AKS, both in the 
concentration range 0.01-0.1 mg·ml-1. 
ULTRAVIOLET-VISIBLE SPECTROSCOPY 
API concentration in solution were evaluated through UltraViolet Visible 
(UV-Vis) spectroscopy using a UV-Vis-NIR spectrometer (Cary 5000, 
Agilent technologies). Each time and for each solution, a 5-point 
calibration curve has been obtained. 
 
IN VITRO RELEASE 
API diffusion from different gels was studied using an apparatus 
consisting of a vertical glass diffusion cells (Franz cell) of 6.0 mL volume 
equipped by a Spectra/Por (12000-14000 Dalton MWCO) hydrophilic 
cellulose membrane (Spectrum Lab). The diffusion area was 2 cm2. Gels 
and commercial formulation were employed as a donor phase. The 
receiving phase consisted of acetate buffer at pH 5.0 (AKS) or water 
solution of HCl (pH 1.0) (CTZ). The apparatus was maintained under 
stirring for 72 h at 307 K, during which at scheduled times the receiving 
phase was withdrawn and entirely substituted with fresh receiving phase. 
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Each withdrawn was analysed. Each sample was prepared and analysed 
in triplicate. 
 
IN-VITRO PERMEATION STUDIES 
AKS transepidermal permeation and skin uptake from the different gels 
were studied using vertical Franz diffusion cells and porcine ear skin. Skin 
slices were isolated using an Acculan dermatome (Aesculap) from the 
outer side of pig ears freshly obtained from a local slaughterhouse and 
then stored for at least 24 h at 255 K. Prior to each experiment, the 
excised skin was rinsed with normal saline solution and pre-hydrated by 
floating it in 0.002% (w/v) sodium azide aqueous solution. The skin was 
then sandwiched between the two cells with the stratum corneum side 
upwards. The diffusion area was 2 cm2. AKS-OMS gel and commercial 
formulation were employed as a donor phase. The receiving phase 
consisted of acetate buffer at pH 5.0. The apparatus was maintained 
under stirring for 168 h at 307 K, during which at scheduled times the 
receiving phase was withdrawn and entirely substituted with fresh 
receiving phase. Each withdrawn was analysed using HPLC. Each 
sample was prepared and analysed in triplicate.  
 
HIGH PRESSURE LIQUID CHROMATOGRAPHY 
AKS was derivatized by mixing 100 μl of aqueous solution of the drug with 
300 μl of methanol, 40 μl of NaOH (0.05 M) and 50 μl of a methanolic 
solution of the derivatizing agent (FDNB) (180 mg·ml-1). The obtained 
mixture was heated at 363 K in an air-circulating oven for 10 min, then 
cooled and injected in HPLC. Each solution was separately derivatized 
prior to injection. The HPLC apparatus consisted of an isocratic pump 
(Series 200, Perkin-Elmer instrument) equipped with a μBondapack C18 
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300 mm · 4.6 mm column (particle size: 10 μm; pore size: 125 Å; 
endcapped) (Waters, Milford, MA, USA). The mobile phase was a mixture 
of acetonitrile–water–acetic acid (47:53:0.1 v/v/v) pumped at 1.5 ml/min. 
A spectrophotometric detector (LC 290, Perkin-Elmer) working at 365 nm 
was used. 
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CHAPTER 1: DRUG INCORPORATION 
 
ABSTRACT 
 
Clotrimazole (CTZ) and Amikacin Sulfate (AKS), two active principles 
widely used in dermatology, were incorporated inside Ordered 
Mesoporous Silica (OMS). Three main techniques have been compared: 
incorporation by solution, incipient wetness impregnation and supercritical 
CO2. At the same time six main OMS have been used: MSU-H, MCM41-
1 to MCM41-4 and MSU-H-F. In all cases the pristine OMS were 
characterized by nitrogen adsorption measurement. Numerous 
incorporation parameters have been studied. The amount of incorporated 
CTZ was higher with the scCO2 process (34% by mass), while AKS 
content was higher with the IWI technique (43% by mass). The drug-
containing OMS was characterized by XRD, FESEM, TGA, FT-IR and 
nitrogen adsorption analysis. In all cases the drug resulted amorphous 
and distributed inside the mesopores. 
 
INTRODUCTION 
In the first pioneering work by Vallet-Regi et al.[33], drug incorporation in 
MCM-41 was carried out by adsorption from a solution using hexane as  
solvent. 
Since the long-term toxicity of n-hexane in humans is well known[91,92], 
many other solvents have been studied for the incorporation. For 
instance, Charnay et al.[93]  reported that when highly polar solvents such 
as dimethyl sulfoxide (DMSO), dimethylformamide (DMF) and 
dimethylacetamide (DMA) were used, the amount of adsorbed drug was 
limited, whereas a higher quantity of drug was incorporated when ethanol 
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or hexane were used. The drug incorporation is strongly affected by the 
solvent due to the competition between the drug and the solvent in the 
adsorption [93].  
An answer could be the IWI process. [47] This technique allows the choice 
of less dangerous solvents tackling the problems of solvent removal and 
adsorption competition. Surely, a high drug solubility must be persecuted 
in order to enhance the drug adsorption efficacy. On the other hand, a 
repetition of the IWI could be done to enhance the drug content. 
Finally, also the incorporation through scCO2 is an alternative way to 
adsorption or impregnation from a liquid solution. Unfortunately, not all 
drugs can be solubilized by the CO2 flow. Even if pressure and 
temperature can modify the solubility parameter of CO2, salts like AKS 
cannot be solubilized. 
Belhadj-Ahmed et al. [94] investigated the supercritical impregnation of 
vitamine E acetate on silica matrixes by means of a dynamic technique. 
Min et al. studied the incorporation of ibuprofen inside SBA-15 through 
scCO2 [95], showing that the loaded drug quantity increased with a higher 
solubility of ibuprofene in scCO2.  
The first paragraph of this chapter will discuss the positive aspects of the 
scCO2 process compared to the incorporation from solution. For the sake 
of brevity, only OMS of MSU-H type will be presented in this part. CTZ is 
the model drug and ethanol, for safety reasons, is the selected solvent. 
Secondly, the scCO2 process will be replied on the MCM-41 OMSs, 1 to 
4. 
Thirdly, the IWI method will be studied for AKS in order to compare the 
two techniques, using two different OMS (MSU-H and MSU-H-F). 
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1.1 SOLUTION AND SCCO2  PROCESS COMPARISON 
 
The effect of the scCO2 treatment on the structure and morphology of 
OMS was investigated by means of XRD and FESEM prior to the 
incorporation of CTZ. The target was to study the possible effects of 
scCO2 on OMS. There was no literature on this topic.  
As it is reported in “Incorporation of clotrimazole in ordered mesoporous 
silica by supercritical CO2” by Gignone et al.[8], wide angle XRD patterns 
and FESEM micrographs showed no significant modifications.  
ScCO2 was used to incorporate CTZ using the apparatus showed in the 
experimental section. Pressure and time of the scCO2 treatment were 
varied, in order to investigate the effect on the amount of incorporated 
CTZ, whereas the temperature was maintained constant and equal to 373 
K. This temperature was chosen significantly higher than the critical 
temperature of carbon dioxide, at variance with what was reported by 
Belhadj-Ahmed et al. [94] and by Min et al. [95]. Thermal degradation of CTZ 
can be ruled out since it was reported to occur at 453 K.[96] The selected 
working pressures ensured a good solvent power of the fluid. The density 
and solubility parameter were respectively equal to 550 kg·m-3 and 9.1 
(MJ·m-3)1/2 at 25.0 MPa, while they were 819 kg·m-3 and 12.5 (MJ·m-3)1/2 
at 50.0 MPa. 
As a whole, four different incorporation procedures were carried out and 
their typical parameters are summarized in Table 1.1, together with the 
corresponding loading of incorporated CTZ, which was measured by TG 
analyses. 
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Table 1.1: Incorporation process parameters for scCO2 and ethanol solution 
(EtOH) and corresponding CTZ loading evaluated by TG analysis.  
Incorporation 
Procedure 
Time 
(h) 
Temperature 
(K) 
Pressure 
(MPa) 
Drug-
OMS 
ratio* 
Loading 
(%) 
scCO2 -1 6 373 25.0 1:1 12 
scCO2 -2 12 373 25.0 1:1 30 
scCO2 -3 12 373 50.0 1:1 34 
scCO2 -4 18 373 25.0 1:1 30 
EtOH 24 298 0.1 3:1 9.0 
*mass ratio 
The maximum amount of incorporated CTZ, corresponding to 34% by 
mass, was obtained at 50.0 MPa after a 12-hours-supercritical treatment.  
Data in Table 1.1 reveal that time plays a crucial role up to 12 hours. In 
fact, the CTZ loading increased from 12% to 30% by mass when time 
increased from 6 to 12 hours at 25.0 MPa, whereas no further increase 
was observed when the process was carried out for a longer time, i.e. 18 
hours, at the same pressure. These data suggest that after 12 hours the 
equilibrium between CTZ in scCO2 and CTZ inside the MSU-H was 
reached.  
At variance, pressure was observed to affect the incorporated amount 
only at a minor extent, since an increase from 25.0 MPa to 50.0 MPa 
yields a limited increase of the CTZ percentage (from 30% to 34%), 
probably due to a higher solubility of CTZ in scCO2 at higher pressure.  
It is worth noting that the incorporation via scCO2 was largely more 
efficient than that obtained by adsorption from ethanol solution. In fact, in 
the latter case the percentage of CTZ inside MSU-H was only 9.0%. 
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Moreover, the amount of CTZ used for the adsorption was three times 
higher than that of MSU-H, at variance with the scCO2 treatment for which 
the same amounts of CTZ and MSU-H were used.  
As already reported[8] CTZ is maintained in an amorphous state. The lack 
of crystallization is crucial, because amorphous drugs are widely accepted 
to have higher aqueous solubility and dissolution rate than related 
crystalline phases. This effect may be particularly important when 
molecules poorly soluble in water, such as CTZ, are considered.[41,97,98] 
FT-IR spectroscopy, nitrogen adsorption measurements and TG analysis 
on this samples showed important details of the CTZ distribution; but this 
correlation will be discussed altogether in the following chapters. 
 
1.2 MCM-41 SCCO2  INCORPORATION 
 
MCM-41 silicas have been widely studied used as drug carrier. During 
this research work, through the solution technique, the maximum CTZ 
content was about 6% by mass without residue mesoporosity. These data 
are different from the MSU-H case, see table 2.1. 
In this case four MCM-41 have been synthesized, as already described, 
and characterized. 
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Figure 1.1: MCM-41 nitrogen adsorption isotherms. Pore volume, SSA and 
PSD are reported in chapter 2. 
Table 1.2: MCM-41 nitrogen adsorption results 
OMS 
Mean pore 
diameter  (nm) 
NLDFT SSA 
(m2g-1) 
NLDFT Volume 
(cm3g-1) 
MCM41-1 4.88 812 1.286 
MCM41-2 4.88 585 1.100 
MCM41-3 3.65 930 0.818 
MCM41-4 2.94 840 0.598 
 
The nitrogen adsorption analysis showed a good SSA and pore volume.  
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Figure 1.2: MCM-41 FESEM images. In the upper left image MCM41-1 is 
showed (mean particles size 360 nm). Upper right, MCM41-2 (210 nm). Lower 
left, MCM41-3 (100 nm). Finally, MCM41-4 (1090 nm). 
 
The drug content with the scCO2 was higher than for the MSU-H case. 
The higher loading was obtained with MCM41-1 with a CTZ content of 
44% by mass. XRD and FTIR analysis reported a complete amorphization 
of the drug. 
 
1.3 AMIKACIN SULFATE INCORPORATION 
 
The drug loading was performed by the solution method and the IWI 
procedure. In the first case, 300 mg of AKS where solubilized in 5 ml of 
H2O and stirred for 24h with 100 mg of MSU-H-F. The water content was 
removed trough filtration and drying. For IWI, typically, 1 ml of a water 
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saturated solution of AKS was added drop by drop to one gram of MSU-
H-F (0.898 cm3·g-1) during mechanical agitation. The homogeneous wet 
powder obtained was vacuum dried for 24 hours to 0.1 Pa obtaining a dry 
powder. 
 
Figure 1.3: (I) XRD spectra of AKS powder (a) and MSU-H-F-AKS (47% by 
mass) (b). (II) FTIR spectra of MSU-H-F (a), AKS in KBr (b) and MSU-H-F-AKS 
(c). (III-IV) N2 isotherms and PSD of MSU-H-F (a) and MSU-H-F-AKS (47% by 
mass) (b).  
In order to control the physicochemical properties of our samples, a 
complete characterization of all samples has been done. XRD results 
shown a complete amorphization of APIs (Figure 1.3). The lack of 
crystallization in these materials is a very well reported and crucial 
phenomenon [40,99,100]. Indeed, such application that require a dissolution 
and diffusion rate in gels able to overcome the skin absorption it is even 
more essential; i.e. crystalline APIs could have a dissolution rate too slow 
in order to maintain the saturation point.  
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In figure 1.4 are shown the low angle XRD diffraction pattern presenting 
the typical (100), (110) and (200) peaks, related to the ordered hexagonal 
(P6mm) network of mesopores. The maintenance of the peaks after the 
incorporation process demostrate the mesostructure preservation. The 
differences in the peak intensity indicate the drug incorporation: less 
density differences from the silica wall to the mesoporous pore core due 
to the incorporated AKS reduce the intensity of the diffracted X-ray. 
 
Figure 1.4: (I) Low angle XRD spectra of MSU-H-F (a) and MSU-H-F-AKS (47% 
by mass) (b). (II) DLS of MSU-H-F after 5 minute of high shear homogenization 
(30 krpm)  
FTIR spectroscopy reveals that the APIs interact with the silica surface 
through Hydrogen bonds with silanols. The adsorption infrared spectra of 
figure 1.3.II describes direct interaction between MSU-H-F and AKS. The 
MSU-H-F as such shows two main band: free silanols at 3742 cm-1 and 
interacting silanols at 3520 cm-1. The 2800-3000 cm-1 bands are the alkyl 
residual chain of the template after the calcination step required to 
produce MSU-H-F. AKS in KBr shows low adsorption between 3550 and 
3160 cm-1 (-NH2, -NH, -OH groups), 2927 and 2850 cm-1 (CH2, CH 
groups) and strong mode at 1640 and 1550 cm-1 (-CONH- group) [67]. 
Other adsorption band of -CO group are under the silica cut-off. In the 
MSU-H-F-AKS sample no free silanols are observable (3742 cm-1) 
suggesting a direct interaction between surface silanols and AKS. 
Moreover, some new broad absorption band are observable in 
I II 
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comparison with AKS in KBr. These are attributed to SiOH interacting with 
different groups of AKS.  
TG analysis reports the API-incorporated quantities. UV-Vis spectroscopy 
results and HPLC quantification confirms these results. The TG 
measurements show in the best case (IWI) an incorporated quantity of 
47% by mass, while with the incorporation by solution it was possible to 
reach only a 15% by mass. 
Nitrogen adsorption isotherms (Figure 1.3.III) return the specific surface 
area, the specific pore volume and the pore size distribution of MSU-H-F 
and MSU-H-F-AKS (Figure 1.6.IV). In the case of IWI, NLDFT specific 
surface area decreased from 625 m2·g-1 to 69 m2·g-1. The pore volume 
decreased from 0.898 cm3·g-1 to 0,121 cm3·g-1. Using the TG analysis 
results, the volume excluded from N2 adsorption, due to the incorporation 
of AKS in MSU-H-F, can be corrected, as already showed in a previous 
paper.[8] Dividing the API incorporated quantity with this corrected 
excluded volume the estimation of the amorphous AKS density is: 1.59 
g·cm-3. The experimental density of crystalline AKS, evaluated with a 
helium pycnometer (Ultrapyc 1200e of Quantachrome) is 1.60 g·cm-3 that 
is in agreement with the unique literature data of Bau et al. [101], to the best 
of our knowledge. This correlation shows that AKS have almost the same 
density in the amorphous and crystalline state. In addition to this, the 
NLDFT PSDs show a reduction of the volume without a change in pore 
diameter (Figure 1.3.IV). These considerations, compared to other 
literature results [99], strongly suggest that AKS molecules are 
incorporated inside the mesopores but not uniformly distributed on the 
MSU-H-F surface. Consequently, with the IWI method, the homogeneity 
inside the mesopores is lost but no occlusion is present and the drug still 
in an amorphous state. This results are confirmed also with the 
incorporation by solution, but the incorporated quantity is much lower. On 
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the other hand, as observable in chapter 2, the scCO2 process is able to 
homogenize the adsorbed drug. 
 
Figure 1.5: FESEM images of MSU-H-F aggregates. 
Figure 1.5 reports a morphological image of MSU-H-F showing 
aggregates of microns composed by particles of about 500-600 nm. The 
primary particles resemble short prism of hexagonal base with striping 
along the height recalling the ordered hexagonal (P6mm) symmetry. The 
DLS measurements of MSU-H-F as such agree with the FESEM image, 
resulting in aggregates of 1300 nm mean value. Indeed, after high shear 
homogenization (5 min at 30 krpm), MSU-H-F particles results completely 
disaggregates (Figure 1.6.II). The mean value is 569±16 nm. The Zeta 
Potential measurements show an instability of the mixture (-12 mV) but 
the probable re-aggregation should be avoided in a future gel use due to 
viscosity.  
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The ions extracted from the MSU-H-F of MSU-H type were Cl-, F-, NO3- 
and SO42-. Sulfate is the only one over 2 ppm (18 ppm). This is not a 
problem since the API used for in-vitro permeation studies is AKS. 
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CHAPTER 2: CLOTRIMAZOLE CHARACTERIZATION IN MSU-H & 
MCM-41 
 
ABSTRACT 
 
The knowledge of the specific interactions between the surface of 
mesoporous silica and drugs is necessary to guide development of new 
and improved drug delivery systems. However, such knowledge is still 
scarce, due to the arduous interpretation of experimental results. This 
chapter reports the complete characterization of the interaction of CTZ, 
inside OMS by means of a joint computational and experimental 
approach. Experimentally the drug was loaded through scCO2 in MSU-H 
and MCM-41. Its adsorption was investigated through FTIR, N2 adsorption 
measurements, TG analysis, SSNMR spectroscopy. Modelling involved 
static and dynamic Density Functional Theory simulations of CTZ 
adsorbed on realistic models of amorphous silica surfaces. In the first part, 
a more simplified approach is reported. The second part informs about 
the agreement between the computational and experimental results, 
concerning the energies of adsorption, the IR spectra and the distribution 
of drug inside the mesopores. Finally, a tentative description of the 
mobility at room temperature of CTZ on the silica surface was done using 
molecular dynamics simulations and SSNMR results. 
 
2.1 DRUG DISTRIBUTION TYPES IN OMS  
 
On the same sample of chapter 1 (MSU-H and MCM-41), nitrogen 
adsorption isotherms were measured to characterize the SSA, the specific 
pore volume and the PSD of OMS as such and OMS-CTZ. In figure 2.1 
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are reported the adsorption and desorption branches for OMS and OMS-
CTZ. 
 
Figure 2.1: Isotherms of MSU-H (I) and MCM41-1 (II) before (a) and after (b) 
scCO2.  
Table 2.1: NLDFT and TGA elaborated data of the isotherms of figure 2.1 
Sample SSA [m2/g] Volume 
[cm3/g] 
Loading 
[gCTZ/gTOT] 
Residual 
Volume  
[cm3/g] 
MCM41-1 813 1.28 46 % 0.29 
MSU-H 597 0.90 34 % 0.32 
 
As already described in a published article[8], from the grams of CTZ 
incorporated inside the sample, the volume occupied by CTZ can be 
calculated and the residual free mesopore volume in OMS-CTZ can be 
estimated. This estimation is strongly affected by the density considered 
for CTZ in the calculation. Assuming a density of 1.316 g/cm3,[66] the 
mesopore volume in OMS-CTZ resulted equal to 0.336 cm3/g. This value 
is in fair agreement with table 2.1. The discrepancy of 0.047 cm3/g may 
arise from the value of CTZ density used in the calculation. Indeed, XRD 
pattern showed that CTZ in OMS lacks of crystalline form and its density 
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is likely to be lower than that of the crystalline phase. These 
considerations can be repeated for the MCM41-1 sample.  
 
Figure 2.2: PSDs of MSU-H (I) and MCM41-1 (II) before (a) and after (b) scCO2. 
The red curve (c) reports the mathematical model calculations. 
Observing the PSDs reported in figure 2.2, obtained from the nitrogen 
sorption isotherms of figure 2.1, it can be said that, for OMS as such (a) a 
main family of pores with an average diameter of 8.5 nm and 5.0 nm are 
observable. On the other hand, after scCO2 (b), these families of pores 
are not anymore present.  
In the case of MSU-H, the presence of smaller mesopores, could describe 
a phenomenon of internal coverage of mesopores surfaces by CTZ 
molecules. Consequently, an attempt has been made to model the 
occupation of mesopores as a layer of CTZ molecules. The volume V0 of 
a single cylindrical empty mesopore is given by 
 
(1)                              𝑽𝟎 =
𝝅
𝟒
∙ 𝒅𝟎
𝟐 ∙ 𝒉 
 
where d0 is the mesopore diameter and h is the mesopore elongation. The 
volume V1 of a single cylindrical mesopore occupied by the clotrimazole 
layer is given by 
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(2)                             𝑽𝟏 =
𝝅
𝟒
∙ 𝒅𝟏
𝟐 ∙ 𝒉 
 
where d1 is calculated as 
 
(3)                             𝒅𝟏 =  𝒅𝟎 − 𝟐𝒅𝒄𝒍𝒐 
 
and dclo is the diameter of a clotrimazole molecule considered as a sphere. 
Combining equation 1 and 2, equation 4 is obtained, which, substituting 
d1 as in equation 3, gives rise to equation 5. 
 
(4)                             
𝑽𝟎
𝑽𝟏
=
𝒅𝟎
𝟐
𝒅𝟏
𝟐 
 
(5)                             𝑽𝟏 =
(𝒅𝟎− 𝟐𝒅𝒄𝒍𝒐)
𝟐
𝒅𝟎
𝟐 ∙ 𝑽𝟎 
 
A new pore size distribution can be calculated from this equation, on the 
basis of the values of V0 and d0 of the pore size distribution of OMS as 
such (Figure 6a), experimentally obtained by the nitrogen adsorption 
isotherm. In order to do so, V0 and V1 in equation 5 have to be normalized  
to the same quantity of silica, because V0 is a specific pore volume, 
expressed in cm3·g-1. This means that, if gsil is the amount of OMS as such 
(silica), the amount of OMS-CTZ is gsil + gclo, where gclo has been 
evaluated by TG analysis. Accordingly, equation 5 is rewritten as equation 
6. 
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(6)                             𝑽𝟏 =
(𝒅𝟎− 𝟐𝒅𝒄𝒍𝒐)
𝟐
𝒅𝟎
𝟐 ∙ 𝑽𝟎 ∙
𝒈𝒔𝒊𝒍
𝒈𝒔𝒊𝒍+𝒈𝒄𝒍𝒐
 
 
This calculation is based on a simple modelization of CTZ molecules 
equally distributed inside MSU-H pores. Figure 2.3 represents 
schematically the above considered type of adsorption.  
 
Figure 2.3: Pictorial representation of CTZ adsorption in mesopores; MSU-H 
(I) and MCM41-1 (II).  
Using these assumptions, from the PSD of OMS as such a theoretical 
PSD, after the adsorption of drug, can be calculated. This is in agreement 
with previous data reported for itraconazole by Mellaerts et al.,[48] who 
observed a molecular dispersion of the drug in OMS. 
On the other hand, these simplified distributions do not take into account 
roughness, density profiles and curvature of the channels surfaces.[102] 
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Consequently, a more detailed description have been done later in this 
chapter with the theoretical help.  
In the case of MCM41-1, due to the fact that there is no residual PSD after 
the scCO2 process (Figure 2.2), these considerations are not valid. 
Indeed, the connection between nitrogen adsorption data and TG analysis 
demonstrate a complete filling of the mesopore channels. A detailed 
description will be reported in chapter 3. In any case, figure 2.3.II reports 
pictorially these differences. 
 
2.2 EXPERIMENTAL AND THEORETICAL DATA 
 
In order to describe better the drug-silica interactions the MSU-H and 
MCM41-1 incorporated samples were used as models, joining 
experimental and theoretical data. This work was done in collaboration 
with the Theoretical Chemistry Group of Prof. Piero Ugliengo, with Dr. 
Massimo delle Piane and Dr. Marta Corno. 
CLOTRIMAZOLE: MOLECULE AND CRYSTAL 
 
CTZ was modeled both in gas phase and as a crystal, before studying its 
adsorption on amorphous silica. The starting point was the X-ray 
experimental structure by Song et al.[66]  
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Figure 2.4: a) 3D space filling model of the CTZ tetrahedral. b) CTZ 
electrostatic potential mapped on the electron density.  
 
The CTZ crystal has been optimized with and without Grimme’s correction 
and compared to experimental results (Figure 2.5).  
 
Figure 2.5: CTZ crystal and molecule-faces interactions: a, CTZ crystal with 
highlighted faces. b, c and d are the PBE-D2 optimized structures of (100) (010) 
and (001) crystal surfaces with one CTZ molecule per cell adsorbed, respectively. 
The added molecule is in blue to distinguish it from the clotrimazole crystal slab. 
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The structure is triclinic with two drug molecules per unit cell. The PBE-D2 
cohesive energy of crystalline CTZ has been computed as -146.5 kJ·mol-1 (Table 
1) and, unsurprisingly, the interactions occurring in the crystal are dominated by 
dispersion (78%).  
Experimentally, the lack of crystallization of CTZ inside OMS is observed. 
This phenomenon has been described in literature both as a confinement 
effect[41,98,103,104] and as a competition between crystal cohesion and 
adsorption on the silica surface.23 To describe this competition, we have 
modelled the interaction of CTZ molecules with three crystalline surfaces 
of the same CTZ crystal, figure 2.5. The added CTZ molecule maximizes 
the contact with the surface molecules mainly through dispersion and 
electrostatics interactions. Unsurprisingly, the interaction energies of CTZ 
with its crystal surfaces are comparable to each other with an average 
value of -113 kJ·mol-1, lower than the crystal cohesive energy (-132 
kJ·mol-1). Experimental TG desorption analysis of crystalline CTZ shows 
an experimental enthalpy of vaporization of about 92 kJ·mol-1, reasonably 
close to the theoretical values. The comparison between computed and 
experimental cohesive energy for the CTZ crystal shows some 
overestimation due to the PBE-D2 method.  
CLOTRIMAZOLE ADSORPTION ON THE SILICA PORE WALL 
 
Experimentally, CTZ was loaded into MSU-H through scCO2, achieving a 
maximum drug loading of 34% by mass. 
In the simulations, CTZ was adsorbed on a silica surface model described 
in a previous study by some of us.[105] This surface exhibits a silanol 
density of 4.5 OH·nm-2, close to the experimentally measured value for 
fully hydroxylated surfaces (4.9 OH·nm-2).[106] Of these silanols, only one 
is free, while the others are interacting through H-bonds. Particularly, 
three SiOHs cooperates in forming a stable H-bonded chain.  
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CTZ was manually docked on the surface, aiming at maximizing the 
interactions between exposed silanols and the different drug’s functional 
groups. In order to match the experimental conditions, six main starting 
geometries have been studied. Four of them are characterized by one 
molecule per silica unit cell (drug loading ~13% by mass), while the other 
two simulate a molecular layer as observed in previous results[8] with two 
and three molecules per unit cell (drug loading ~27% and ~41% by mass, 
respectively) (Figure 2.6). 
 
Figure 2.6: View along the z axis of the fully optimized six different geometries 
of adsorption. a) imidazole (I). b) imidazole (II). c) phenyls (I). d) phenyls (II). e) 
molecular layer (I): two molecules per silica unit cell. f) molecular layer (II): three 
molecules per unit cell.  
INTERACTIONS AND ENERGETICS BETWEEN CLOTRIMAZOLE AND 
THE SILICA PORE WALL 
 
From all the six geometries of figure 2.6, four main types of interaction 
between CTZ and silanols are observable, figure 2.7. The imidazole ring 
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can form both two (Figure 2.7.a) and one (Figure 2.7.b) H-bonds with the 
surface. H-bonds of the Si-O-H---Cl type (Figure 2.7.c) are weaker than 
those with imidazole. Several SiOH-π (surface-CTZ, Figure 2.7.d) have 
been observed in almost all the different structures, while π-π edge to 
face lateral interactions (CTZ-CTZ) characterize the molecular layer 
models. 
 
Figure 2.7: Silica-CTZ types of interactions.  
An essential result that these considerations reveal is that all the 
computed interaction energies and enthalpies are close to each other, 
enlightening a possible competition between crystalline and adsorbed 
CTZ. Assuming that the supercritical incorporation is a step route 
controlled by dissolution and adsorption of single molecules, this process 
is almost isoenergetic, since for each adsorption on silica an average of 
110 kJ·mol-1 are gained and for each desorption from the crystal 115 
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kJ·mol-1 are lost. This could be the explanation of the lack of crystallization 
in pores smaller than 20 times the molecule diameter explained by 
Sliwinska-Bartkowiak et al.[103] and observed by other authors.[41,98,104] In 
addition TG desorption analysis of CTZ in MSU-H (34% by mass) 
produces an enthalpy of vaporization of 91.6 kJ·mol-1. As 
abovementioned, a similar analysis on crystalline CTZ results in a value 
of 91.8 kJ·mol-1. Thus, also the experimental data suggest that the two 
processes are almost isoenergetic, supporting the hypothesis on silica-
induced drug amorphization.  
MODEL OF ADSORPTION: NITROGEN ADSORPTION AND TG 
ANALYSIS 
 
As previously described, from the experimental N2 adsorption isotherms, 
the PSDs, before and after the scCO2 incorporation of CTZ, can be 
obtained. These show that the drug incorporation reduces the mean pore 
diameter from 86 Å of bare MSU-H to a lower value of 67 Å (figure 2.2). 
Clearly, with the above mentioned approach, the calculated PSDs are 
unable to describe correctly the experimental results.[8] 
 
Figure 2.8: Adsorption model. (I) and (II) side views along the a direction of 
molecular layers (I) and (II), respectively.  
On the other hand, experimental TG analysis reports an incorporated 
quantity of 34% by mass, which is in between the loading calculated for 
layer (I) and layer (II), which are ~27% and ~41% by mass, respectively. 
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By calculating the experimental planar concentration of CTZ (molecules 
per nm2) and comparing it to our theoretical models of molecular layers (2 
CTZs/cell, Figure 2.6.e and 3 CTZs/cell, Figure 2.6.f), it is shown that the 
real system can be described by a 50:50 mixture of the two molecular 
layer geometries. Indeed, the unit cell of the simulated silica surface has 
an area of 1.6 nm2 and the experiment reports 2.5 CTZ molecules per 1.6 
nm2. As a consequence, a simulated MSU-H-CTZ PSD has to be 
calculated, starting from the experimental PSD of bare MSU-H, assuming 
thicknesses representative of both the molecular layer (I) and (II) models. 
These thicknesses have been evaluated following the Connolly 
surfaces[107] before and after CTZ adsorption of the computed models, 
with the purpose to take into account the vdW molecular volume and the 
roughness generated by the statistical distribution of 2 and 3 CTZ 
molecules per 1.6 nm2. Therefore, the molecular layer surfaces have been 
discretized in 677 squares (0.25 Å2) in order to evaluate the thicknesses, 
for each point, between the starting silica model and the molecular layers. 
Subsequently, a new PSD has been calculated for each couple of 
evaluated thicknesses and all curves have been combined together in the 
final theoretical PSD of figure 2.2.I.c. Such procedure results in an 
impressive agreement between simulation and experiment, validating the 
data interpretation. 
INCREASING THE CTZ ADSORBED QUANTITY 
 
Due to the prefect agreement of this modelization, three different samples 
with increasing fillings were prepared using scCO2 process. The aim was 
to obtain information on CTZ interaction with silica pore wall at increasing 
loading. Through XRD analysis it was possible to evaluate the presence 
or not of CTZ crystals. None of the samples show diffraction peaks of 
CTZ. 
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Nitrogen adsorption isotherms, figure 2.9, evidence a linear decrease in 
comparison to the loaded quantity of SSA and pore volume. In table 2.3 
are reported the detailed values. To the best of our knowledge, the only 
literature crystalline CTZ density data is a calculated number reported in 
the work of H. Song et al.[66] Using a helium picnometer, a value of 1.31 
g·cm-3 has been obtained, in perfect agreement with the literature data. 
Interestingly the calculated CTZ density inside the mesopore, reported in 
Table 2.3, increase with the loading but never reach the crystalline 
number. As already demonstrated, the CTZ is amorphous but the linear 
increase of density with the loaded quantity could be due to a decreasing 
pore occlusion. In addition to this, as evidenced by the position and shape 
of the hysteresis loop, the mean pore diameter of the mesoporous 
channels decrease with the formation of the CTZ layer. 
 
Figure 2.9: Nitrogen adsorption isotherms of bare MSU-H (a), MSU-H-CTZ-
12 (b), MSU-H-CTZ-18 (c) and MSU-H-CTZ-34 (d). Below the PSD of bare 
MSU-H (black) in comparison to MSU-H-CTZ samples (blue); the red curve is 
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the theoretical PSD corresponding to the experimental loading; from left to 
right: MSU-H-CTZ-12, MSU-H-CTZ-18 and MSU-H-CTZ-34.  
Through NLDFT the PSD of all samples have been calculated. 
Hypothesizing the adsorption of CTZ as a step process of single 
molecules that lead to the formation of a layer on the silica wall, the 
experimental PSD of MSU-H-CTZ can be calculated.[99] In order to 
evaluate the theoretical PSD of figure 2.9 (red), the theoretical docking 
structure previously described have been used. The same procedure has 
been changed with some correction in order to take into account the low 
loading configuration. Briefly, a new PSD has been calculated for each 
couple of evaluated thicknesses and all curves have been combined 
together in the final theoretical PSD representative of each different 
loading (red). For instance, to evaluate the theoretical PSD of MSU-H-
CTZ-12, the four single docking geometries (Imidazole (I) and (II), phenyls 
(I) and (II)) combined to two clear silica surface (Silica as such) have been 
used as starting thicknesses, resulting in 4056 point of thicknesses. Then, 
more than 16 million of new PSD, one for each couple of thickness, have 
been calculated from the PSD of bare MSU-H and combined together in 
the left red curve of figure 2.9. The use of two clear silica surface is 
required to obtain the correct planar concentration of CTZ. As it is reported 
in table 2.3 a loading of 12% by mass corresponds to a surface coverage 
of 0.4 CTZ·Å-2, that can be expressed using the theoretical model in a 
0.64 CTZ molecule per silica unit cell. 
Table 2.3: Nitrogen adsorption and TG numerical results compared to 
theoretical data  
Samples 
Pore 
volumea 
Loaded 
quantityb 
CTZ 
experimental 
densityc 
CTZ·1.606 
nm-2 d 
MSU-H 0.900 - - - 
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MSU-H-
CTZ-12 
0.650 12 1.0 0.64 
MSU-H-
CTZ-18 
0.529 18 1.0 1.0 
MSU-H-
CTZ-34 
0.290 34 1.2 2.5 
a(cm3·g-1). b(% by mass). c(g· cm3) obtained dividing the loss in pore volume for 
the loaded CTZ quantity, normalized to the grams of silica. d(Number of CTZ 
molecules per theoretical surface area of the silica unit cell). For MSU-H-CTZ-12, 
Imidazole (I) and (II), phenyls (I) and (II) and two clear silica surface have been 
used, obtaining a theoretical planar concentration of 0.66 CTZ / 1.606 nm2. For 
MSU-H-CTZ-18, Imidazole (I) and (II) and phenyls (I) and (II) have been used.  
For MSU-H-CTZ-34, molecular layer (I) and (II) have been used. 
 
SOLID STATE NUCLEAR MAGNETIC RESONANCE 
 
Solid-state NMR measurements were performed in order a) to evaluate 
the inclusion of CTZ in the OMS; b) to quantify the amount of included 
CTZ; c) to evaluate the mobility of CTZ inside the silica. 
The 13C CPMAS spectra of pure CTZ, MSU-H, MSU-H-CTZ-12, MSU-H-
CTZ-18 and MSU-H-CTZ-34 are reported in Figure 2.10, while 1H MAS 
spectra are reported in Figure 2.11. Selected 1H and 13C chemical shift 
values are reported in table 2.4. 
The 13C CPMAS spectra of MSU-H-CTZ-12, MSU-H-CTZ-18 and MSU-
H-CTZ-34 are characterized by broad peaks with respect to pure CTZ 
whose spectrum presents sharp lines typical of highly crystalline systems. 
The strong overlapping of the signals in the aromatic region (110-150 
ppm) prevents any possible assignment. However, the broadness of the 
resonances and the shift of the Csp3 atom on passing from pure CTZ to 
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loaded MSU-H clearly show that CTZ has been included in the cavities of 
the silica. Furthermore, the higher width of the peaks for MSU-H-CTZ-12, 
MSU-H-CTZ-18 and MSU-H-CTZ-34 with respect to pure CTZ proves the 
amorphous character of CTZ inside MSU-H, which is a positive 
characteristic since bioavailability usually increases with the 
amorphization.[97,108] 
 
 
Figure 2.10: 13C (100.65 MHz) CPMAS spectra of pure CTZ, MSU-H-CTZ-12, 
MSU-H-CTZ-18 and MSU-H-CTZ-34. The symbols ▲ denote residues of CH2-
CH3 groups from surfactants involved in MSU-H preparation processes.  
This agrees with the loss of periodicity associated to the inclusion process 
which allows for several possible adsorption ways of CTZ on the silica 
walls as predicted by NLDFT methods.[99] Moreover, at higher loading, the 
predicted formation of amorphous layers still is consistent with the 
observed line widths. 
The 1H MAS spectra are characterized by three main signals (see Table 
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2.4 and Figure 2.11): from spectrum a, the CTZ hydrogen atoms (HCTZ) at 
6-7 ppm (III); from spectrum f, free SiOH groups (I) at 1.8 ppm in 
accordance with the literature;[109] finally, from spectrum b, the SiOH 
groups in interaction with H2O (SiOH-H2O) at 4-5 ppm (II). The symbols 
▲ denote the impurities derived from the silica synthesis (2-5 ppm). 
Indeed, as also showed by the FTIR spectra, in accordance with the 
literature,[110] these are -CH2 and -CH3 residues of the involved surfactants. 
The small differences in the chemical shifts among all samples are related 
to the different environment and crystal packing of the CTZ molecules in 
the silica, from isolated sites to layers.  
Table 2.4: 1H and 13C selected chemical shifts (δ) with assignments for CTZ, 
MSU-H, outgassed MSU-H, MSU-H-CTZ-12, MSU-H-CTZ-18 and MSU-H-CTZ-
34.   
Compound 
13C 1H 
C-C-Cl C-N Csp3 CHCTZ 
SiOH-
H2O 
Free 
SiOH 
CTZ 145.1 119.1 75.3 6.1 - - 
MSU-
Houtgassed 
- - - - 4.0 1.8 
MSU-H - - - - 
4.2/ 
6.0sh 
- 
MSU-H-
CTZ-12 
145.0 
120.4-
119.8 
75.9 6.4 4.3 - 
MSU-H-
CTZ-18 
144.0sh 121.6sh 76.0 7.0 5.2 - 
MSU-H-
CTZ-34 
not 
detectable 
not 
detectable 
75.6 6.5 3.8sh - 
sh shoulder. bb broad band. 
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Figure 2.11: 1H (400.23 MHz) MAS spectra of pure CTZ (a), MSU-H (scCO2 
treatment) (b), MSU-H-CTZ-12 (c), MSU-H-CTZ-18 (d), MSU-H-CTZ-34 (e) 
and MSU-H (outgassed) (f).  
The most important information can be extracted from the variation of the 
relative intensities of the signals. Indeed, while the MSU-H spectrum (b) 
is almost completely dominated by the SiOH-H2O signal, the spectra of 
MSU-H-CTZ-12, MSU-H-CTZ-18 and MSU-H-CTZ-34 are characterized 
by a progressively enhancement of the signal around 6-7 ppm attributed 
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to HCTZ atoms. Furthermore, the SiOH peaks reduce their intensity on 
passing from pure MSU-H to MSU-H-CTZ-34, from lowest to highest 
loading. 
As already reported in table 2.4, from the experimental TG results, in 
comparison to the N2 adsorption measurements, the number of CTZ per 
theoretical surface area of the silica unit cell (1.606 nm2) can be 
evaluated. This value, in table 2.5, has been reported as molecules per 
square nanometre. With the same approach, also the H2O content has 
been calculated.  
Table 2.5: Correlation between experimental TG analysis, N2 isotherms, 
theoretical molecule distribution and SSNMR. 
TGa CTZ·1.606 nm-2 b CTZc H2Od HCTZ e HSiOH-H2O f SSNMR g 
0 0.00 0.00 4.5 0.0 13.5 - 
12 0.64 0.40 3.0 7.0 10.5 1.0:1.6 
18 1.00 0.62 3.0 10.6 10.5 1.0:1.0 
34 2.50 1.56 0.0 26.5 4.5 - 
a(% by mass) obtained from TG analysis (Figure S1), b(Number of CTZ molecules 
per theoretical surface area of the silica unit cell), c(CTZ molecules per nm-2) 
obtained from TG results and NLDFT elaboration of experimental nitrogen 
adsorption isotherms, d (H2O molecules per nm-2) obtained from TG results and 
NLDFT elaboration, e(HCTZ·nm-2), f(HH2O·nm-2), gSSNMR ratio between the peaks 
attributed to HCTZ and HSiOH-H2O. As free SiOH surface concentration the value of 
4.5 SiOH·nm-2 has been used, in agreement with the theoretical model surface 
concentration.[99]  
The obtained value of 3.0 H2O·nm-2 from thermogravimetric analysis, 
compared to the chemical shift of  4.2 ppm, is in agreement with the 
literature.[111] Indeed, Grünberg et al. reported a value of 4.0 ppm with a 
surface coverage of 3.6 H2O·nm-2.  
The integral values, obtained from the deconvolution analysis of 
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quantitative 1H spectra, of the CTZ and SiOH-H2O signals at 6.1-7.0 and 
3.8-6 ppm, respectively result to be consistent with the previously reported 
CTZ-silica ratios per unit cell.[99] Indeed, for instance, the 1H spectrum of 
MSU-H-CTZ-12 is characterized by a relative intensity of the HSiOH-H2O and 
the HCTZ resonances of 1.6 to 1. This is consistent with the reported data 
of 0.64 CTZ·1.606 nm-2, experimentally obtained and theoretically 
confirmed. Accordingly, in the MSU-H-CTZ-18 situation the HCTZ and 
HSiOH-H2O signal intensities are comparable (1:1). This, again, is coherent 
with the experimental and theoretical evidenced mode of interaction. On 
the other hand, a slight chemical shift of the MSU-H OH peaks is evident. 
This small shift has been attributed to an increase of H-bonds between 
SiOH and CTZ, as evidenced by FTIR and theoretical calculations. 
Indeed, other SSNMR analysis of guest molecules evidenced this 
chemical shift. Of particular interest is the work of Shenderovich et al.[112] 
reporting the chemical shift of SiOH in interaction with pyridine (9.9 ppm). 
For the same reason, hypothesizing a higher chemical shift, in the case 
of MSU-H-CTZ-34, no ratio has been evaluated. 
It can be concluded that, during the scCO2 process, the CTZ molecules 
slowly replace H2O molecules in the H-bond interaction with SiOH. 
Indeed, the number of H-bonds formed remains constant, changing the 
guest molecule. The reasons should be a stronger interaction of the SiOH-
CTZ, as evidenced by higher FTIR redshift, theoretical energy of 
interaction and experimental energy of desorption.[99] On the other hand, 
has been evidenced by theoretical calculation that an interaction between 
SiOH and guest molecule is favoured by the H2O presence.[113] 
Consequently, the cause remains uncertain and could include the 
hydrophobicity nature of CTZ that, during scCO2 process, builds up a 
hydrophobic molecular layer. 
Since, often, the ability of the controlled release of a host molecule inside 
a guest is also related to its mobility, the dynamic of CTZ inside the silica 
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has been probe through relaxation measurements. Thus, 1H T1 relaxation 
time measurements were performed on all the samples. Indeed, in the 
solid state, the T1 is strongly related to the strength of the dipolar 
interaction, which directly depends on the presence of fluctuating 
magnetic fields generated by the dynamic behaviors of the whole 
molecule or of parts of it. 
MOBILITY OF ADSORBED CLOTRIMAZOLE 
 
Ab-Initio Molecular Dynamics (AIMD) has been performed on the different 
statically optimized geometries in order to evaluate the stability of the local 
minimum structures of figure 2.6. Detailed data are reported in a published 
article.[99] AIMD simulation on the molecular layer (II) structure shows high 
mobility of the three CTZs (per unit cell) on the surface. The RMSD of the 
atomic positions along the AIMD simulation shows a large movement 
between 4 and 7 ps that results in a new configuration, with a RMSD value 
of 4.3 Å with respect to the starting CTZ conformation after 11 ps. The 
process is described in Figure 2.12, where the exposed nitrogen atoms of 
the imidazole rings of the three adsorbed molecules in each unit cell are 
referred as N1, N2 and N3. The graph in Figure 2.12.a, reporting the N1-
SiOH_III and N1-SiOH_I distances, clearly shows a transition state where 
the chain is lost and the imidazole’s nitrogen (N1) is equidistant from 
SiOH(I) and (III). Looking at the potential energy fluctuations during this 
simulation, we estimate, in a very approximate way, the electronic 
activation energy of this process as 29.7 kJ·mol-1 that can be considered 
an upper limit for the real value.  
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Figure 2.12: AIMD of the molecular layer (II) structure: a) N1-SiOH(I) and N1-
SiOH(III) bond distances in time. b) starting (A) and final (B) positions of N1 and 
N2 with respect to the involved SiOHs. c) Top views of the initial (left) and final 
(right) configurations in the AIMD simulation, with the corresponding interaction 
energies per CTZ molecule (kJ·mol-1); cell borders in pink.  
These AIMD results are in accordance with the experimental finding of a 
“liquid like” behavior of ibuprofen adsorbed in MCM-41.[42,43] Considering 
that CTZ is much more hydrophobic than ibuprofen it is no surprise that 
CTZ molecular layers are very mobile, despite the significant underneath 
interactions. This mobility can be represented as a walking step process 
guided by local changes in the H-bond interactions, helped by a high 
flexibility of the silica surface silanols. 
From an experimental point of view, the 1H T1 relaxation time of SSNMR 
increases from 0.1 s to 80 s by increasing the CTZ loading from MSU-H-
CTZ-12 to MSU-H-CTZ-34. This can be attributed to a reduction of 
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mobility of CTZ inside the silica on passing from the isolated CTZ 
molecules (higher mobility for low loading) to the formation of a layer 
(lower mobility for high loading) as previously described.[99] Conversely, 
pure CTZ is characterized by a 1H T1 of 90 s, typical of very rigid crystal 
packing. Summarizing, the evidenced mobility in the molecular dynamics 
simulations obtained by some of use[99] follows frankly the SSNMR 
relaxation times. Indeed, in the case of single docking (Imidazole (I) and 
(II), phenyls (I) and (II)) high energetics phenomena are observed like lose 
and acquire of H-bonds due to CTZ movement or rotation in place. On the 
other hand, the molecular layers (I) and (II) show higher cooperation 
moving as a layer on the silica surface but not among them. 
EXPERIMENTAL AND THEORETICAL FTIR INTERPRETATION 
 
Experimental and theoretical vibrational spectra of CTZ in molecular, 
crystalline and adsorbed environments have been obtained[99]  
Figure 2.13 reports both the experimental (blue line) and the theoretical 
(red line) IR spectra of CTZ in interaction with silica at low and high 
coverage. The low coverage experimental spectrum has been acquired 
on a MSU-H-CTZ sample with a drug loading of 18% by mass, while the 
high coverage corresponds to a drug loading of 34% by mass. As regards 
the simulated spectra, the CTZ modes have been obtained in both cases 
from a vibrational analysis in the harmonic approximation of the drug in 
the four single molecule configurations, combined by Boltzmann 
weighting their contribution to the infrared intensity according to the 
computed interaction energies.  
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Figure 2.13: Experimental and simulated IR: experimental FTIR spectrum of 
MSU-H-CTZ (blue); theoretical IR spectrum of CTZ combined with SiOH 
vibrational contribution (red); simulated IR spectrum of SiOH vibrational 
contribution of: imidazole (I) (dot-dashed black line); imidazole (II) (dashed black 
line); phenyls (I) (dotted black line); phenyls (II) (black line). At the bottom of the 
graph, sticks represent the theoretical SiO-H stretching frequencies without 
Pimentel’s correction. 
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For both the low and high loading cases, the agreement between theory 
and experiment is remarkable and helps the interpretation of the signals. 
A more detailed description can be read elsewhere.[99]  
As can be deducted from figure 2.13, increasing the CTZ loading results 
in an increasing number of H-bonds between SiOH and CTZ molecules. 
Indeed, the 3750 cm-1 sharp band, decrease gradually while the 3500-
2600 cm-1 broad band increase. At the highest loading obtained there are 
no free silanols. This shift is attributed to the formation of H-bonds 
between SiOH and CTZ through the exposed nitrogen of the imidazole 
ring. At the same time, other types of H-bonds are formed with the CTZ 
molecules (SiOH-π, SiOH-Cl) that are responsible to the change in the 
3700-3500 cm-1 band. Starting from SiOH-SiOH interaction in the bare 
MSU-H, they evolve gradually in a mixture of the same H-bonds mixed to 
interactions with CTZ (SiOH-π and SiOH-Cl). To demonstrate this, the 
broad background at 3700-3500 cm-1 responsible to the increase of the 
3620 cm-1 peak, more substantial in MSU-H-CTZ-12, almost disappears 
in MSU-H-CTZ-34. These conclusions reveal the direct interaction 
between CTZ and mesoporous silica wall until the formation of a CTZ 
molecular layer.  
 
2.3 MCM-41 FILLING MODEL 
 
TG analysis and nitrogen adsorption measurement comparison applied to 
MCM41-1 do not lead to the same conclusions. While FTIR analysis 
presents the same adsorption band, the mesopores of MCM41-1 results 
filled of CTZ molecules without homogeneity. Indeed, no empty pore are 
visible after the scCO2 process. In chapter 3 a more detailed description 
is given, but here are reported preliminary theoretical discussion of a new 
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model of incorporation.  
As mentioned above, in the case of MSU-H, the pore diameter (8.5 nm) 
allows us to consider the silica surface as flat when CTZ is docked. For 
MCM-41 this assumption is not anymore satisfied. Consequently, the 
surface model has been modified following the MCM-41 model presented 
in the article of Delle Piane et al.[84]  
 
Figure 2.14: Longitudinal view of the MCM-41 model (I). (II) and (III) simulation 
of the filled CTZ channel. 
The MCM41-CTZ model has been optimized at PBE-D2 level of theory. 
The basilar information that can be extracted is that 9, out of 11 CTZ 
molecules, are interacting with the silica surface. The last 2 are in a 
position similar to the molecular layer (I) and (II). In addition, the number 
and energies of interactions are higher. This discussion reveals in a 
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simplified way the motivations of the MCM41-1 filling during the scCO2 
incorporation process.  
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CHAPTER 3: SILICAS DETERMING FACTORS IN THE 
INCORPORATION PROCESS 
 
ABSTRACT 
 
The knowledge of the specific interactions between the surface of 
mesoporous silica and drugs took to comprehend the different type of 
adsorption geometries depending on the pore size dimension. However, 
such knowledge is still preliminary.  
In this chapter a complete experimental description on these factor have 
been argued.  Fourteen mesoporous silica have been incorporated trough 
scCO2 process and completely characterized in order to understand the 
experimental discriminant factors. In the first part, a characterization of all 
OMS as such is reported; after that, the different behaviors are described; 
finally, some argumentation are stated.  
 
3.1 OMS CHARACTERISTICS 
 
The 14 mesoporous (Table 3.1) silicas were selected for different 
characteristics and considerations. One mesoporous silica is, to be 
correct, a disordered microporous silica, Syloid. Four MCM-41, were 
synthesized to screen low pore diameter silicas. One commercial MCM-
41 was necessary to avoid laboratory behaviors. Four KIT-6 were 
manufactured to control if Ia3d silicas have the same behavior. Two 
commercial and one synthetic SBA-15 were used to point out the conduct 
with high pore dimension. The MSU-H was reprocessed to control the 
supercritical process and the reproducibility of the results. 
Table 3.1: NLDFT parameter of all the OMS used. They have been ordered 
according to the mean pore diameter that is not ever the maximum of the PSD. 
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OMS 
Mean pore 
diameter  (nm) 
NLDFT SSA 
(m2g-1) 
NLDFT Volume 
(cm3g-1) 
Syloid 1.37 1157 0.378 
MCM41-4 2.94 840 0.598 
MCM41-3 3.65 930 0.818 
MCM41-ACS 4.57 843 0.901 
MCM41-1 4.88 812 1.286 
MCM41-2 4.88 585 1.100 
KIT6-50 5.28 678 0.560 
KIT6-80 6.55 603 0.690 
SBA15 6.79 763 0.697 
KIT6-100 7.86 788 1.157 
MSU-H-F 8.14 643 0.836 
SBA15-ACS 8.14 424 0.884 
MSU-H 8.46 596 0.900 
KIT6-130 10.13 525 1.300 
 
From table 3.1 and figure 3.1.I it can be evidenced that the OMS are 
mainly divided in two categories: silicas with mean pore diameter lower 
than 4.88 nm and silicas higher than this. Indeed, two main straight line 
can be verified from the graph 3.1.I. This categorization is due to the wall 
thickness. It is well clear that MCM-41 and SBA-15 silicas have this 
differences. It is strange that also Syloid and KIT-6 respects this condition. 
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Figure 3.1: Distribution of OMS in function of mean pore diameter and pore 
volume (I).  
All the OMSs have been characterized by TG, XRD, FESEM analysis. No 
important result for this correlation have been noted. 
 
3.2 CHARACTERIZATION OF INCORPORATED OMS 
 
All the OMS have been incorporated through scCO2 at 250 bar and 373K 
for 18 hours. No further incorporation was possible increasing the total 
time. All the characterization analysis already described were repeated 
on the incorporated materials. Absolute data are, first of all, the maximum 
incorporated quantity: 46% by mass obtained with MCM41-1. Secondly, 
in no circumstances crystalline CTZ was observed. Thirdly, all the N2 
adsorption measurements reported a decrease of SSA and pore volume. 
In some cases, also the mean pore diameter was decreased.  
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Figure 3.2 reports some of the nitrogen adsorption measurements done. 
It can be observed that for Syloid and MCM-41, after the supercritical 
process, there is almost no residue porosity (no step or hysteresis) and 
very lower surface area (lower inclination). On the other hand, MSU-H and 
KIT6-130 still have large empty porosity. A border case is the KIT6-50.  
According to chapter 2, it can be argued that the first OMSs are filled of 
CTZ as the theoretical modelization of figure 2.14, while in the second 
group CTZ is adsorbed as a molecular layer, figure 2.8. Trying to 
understand the limiting pore size dimension, a further analysis has been 
done. Figure 3.3 reports the incorporated quantity in function of the 
NLDFT pore volume. In this case the incorporated quantity is calculated 
as the CTZ content on the silica content.  
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Figure 3.2: Nitrogen adsorption measurements before (OMS) and after the 
scCO2 process (OMS-CTZ). 
This correlation evidences which OMSs follows the filling model. On the 
other hand, an R2 of 0.93 is not a good report; but, considering the error 
bars, all the data are consistent. The linear equation has been selected 
without constant term thinking to the fact that the mesopore could be filled 
or empty. On the contrary, in no cases the external SSA was taken into 
account. Indeed, this correlation do not consider the external surface 
coverage that it is hardly estimable.  
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Figure 3.3: OMS correlations: Incorporated Quantity (gCTZ/gsil) versus NLDFT 
Pore Volume (cm3/gsil). The red dot reports a border linearity. 
At the same time, the correlation of NLDFT SSA with incorporated 
quantity has been done and reported in figure 3.4.  
 
Figure 3.4: OMS correlations: Incorporated Quantity (gCTZ/gsil) versus NLDFT 
SSA (m2/gsil).  
In this case R2 is 0.95 and the slope (m) of the linear equation is directly 
correlated to the number of CTZ·nm-2. The results, reported to the surface 
area of the silica theoretical cell (chapter 2), is 1.7 CTZ·cell-1. This result 
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is lower than the presented one of chapter 2 but also the scCO2 conditions 
are lower (250 bar). 
As it is possible to observe, not all the silica follows perfectly these 
relationships. For instance, KIT6-50 and KIT6-80 follow both correlations. 
Consequently, in order to correctly distinguish all cases, the PSD 
simulations have been applied for all the OMSs, taking into account the 
number of CTZ extrapolated from the linear correlation. If it works, it can 
be defined as a molecular layer; on the contrary, it could follow the filling 
correlation. 
The results, reported in figures 3.5 – 3.6 – 3.7, shows three conditions:  
 Figure 3.5: OMSs perfectly filled, without residual porosity. 
 Figure 3.7: OMSs with a molecular layer of about 1.7 CTZ/cell; 
 Figure 3.6: a condition in between. 
Therefore, it seems reasonable conclude that from a mean pore radius of 
5.2 to 6.8 nm the behavior is mixed. Probably, also the Ia3d structure of 
KIT-6 silicas is important. Indeed, the SBA15, which has the bigger mean 
pore diameter, seems to follows better the filling model, but it suffers more 
than the others of low diffusivity (2D pore structure versus 3D.)  
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Figure 3.5: PSD of OMS as such (black), OMC-CTZ (blue) and the calculated 
PSD (red). In brackets the number of CTZ per unit cell used for the model. 
These are the silicas that follows a filling theory. 
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Figure 3.6: PSD of OMS as such (black), OMC-CTZ (blue) and the calculated 
PSD (red). In brackets the number of CTZ per unit cell used for the model. 
These are the silicas border line. 
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Figure 3.7: PSD of OMS as such (black), OMC-CTZ (blue) and the calculated 
PSD (red). In brackets the number of CTZ per unit cell used for the model. 
These are the silicas that follows the molecular layer theory.  
Table 3.2: OMS correlations resume.  
OMS Mean Pore Diameter Correlation 
Syloid 1.37 Pore Volume 
MCM41-4 2.94 Pore Volume 
MCM41-3 3.65 Pore Volume 
MCM41-ACS 4.57 Pore Volume 
MCM41-1 4.88 Pore Volume 
MCM41-2 4.88 Pore Volume 
KIT6-50 5.28 Both 
KIT6-80 6.55 Both 
SBA15 6.79 Both 
KIT6-100 7.86 SSA 
MSU-H-F 8.14 SSA 
SBA15-ACS 8.14 SSA 
MSU-H 8.46 SSA 
KIT6-130 10.13 SSA 
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In conclusion, one more correlation need to be reported. From the NLDFT 
pore volume data and the TG analysis the density of CTZ inside the 
mesoporous volume can be evaluated. The next equation resumes this 
correlation: 
𝐼𝑛𝑐𝑜𝑟𝑝𝑜𝑟𝑎𝑡𝑒𝑑 𝑄𝑢𝑎𝑛𝑡𝑖𝑡𝑦 [
𝑔𝐶𝑇𝑍
𝑔𝑠𝑖𝑙
] = 𝑉′ [
𝑐𝑚3
𝑔𝑠𝑖𝑙
] − {𝑉′′ [
𝑐𝑚3
𝑔𝑠𝑖𝑙+𝐶𝑇𝑍
] ∙ (
𝑔𝑠𝑖𝑙+𝐶𝑇𝑍
𝑔𝑠𝑖𝑙
)} 
where V’ is the OMS NLDFT pore volume as such and V’’ after the scCO2 
process. The incorporated quantity and the ratio (
𝑔𝑠𝑖𝑙+𝐶𝑇𝑍
𝑔𝑠𝑖𝑙
) are obtained 
through TG analysis.  
 
Figure 3.8: Incorporated quantity (gCTZ·gsil-1) versus NLDFT ΔV (cm3·gsil-1): the 
density correlation.  
The straight line has a slope coefficient (m) of 1.14 gCTZ·cm-3. This result 
matches perfectly with all other correlations (chapter 2). In addition to this, 
it can be said that all the OMSs that are not on the straight line suffers of 
pore occlusion. None of these have large amount of CTZ outside the 
mesoporous volume.  
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CHAPTER 4: AKS-OMS GEL 
 
ABSTRACT 
 
A possible and promising area of application for Ordered Mesoporous 
Silica (OMS) is the topical therapy of dermatological diseases and 
wounds. It is widely known that Active Pharmaceutical Ingredient (API) 
incorporated in OMS based materials are adsorbed in the volume in an 
amorphous state and in some cases well distributed on the surface as a 
single molecular layer. This feature is crucial for many aspects: from the 
bioavailability enhancement of molecule poorly soluble in water to the 
effects of reservoir that can be tuned in cream for topical application. 
Indeed, the use of OMS incorporated of API in a saturated vehicle to the 
therapeutic concentration develops a controlled and constant release 
system on the skin site. 
 
Figure 4.1: Ideal description of AKS-OMS gel. 
This chapter describes the development of topical composition able to 
release drug in a sustained and prolonged manner. Incipient Wetness 
Impregnation procedure has been used to load AKS in commercial OMS 
of MSU-H type. The incorporated OMS characterization (XRD, FESEM, 
etc.) are reported in chapter 1. A series of different release test has been 
performed to validate the new release technology (UV-Vis spectroscopy). 
As a result, a semisolid formulation with AKS has been developed. The 
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stability, pH and rheological properties were investigated overtime. In vitro 
release and permeation studies were assessed using an open chamber 
diffusion cell system (Franz cell), fitted with semi-permeable membrane 
or porcine ear skin. All the results emphasize the reservoir effect of OMS 
incorporated of API. In addition, they demonstrate the availability of a new 
topical release technology able to reduce the number of administrations. 
 
4.1 SUSTAINED RELEASE FROM OMS-AKS IN AKS SATURATED 
SOLUTIONS 
 
In order to confirm the reservoir effect of the incorporated OMS in a 
saturated solution composed by two solvents, AKS, a hydrophilic API, has 
been studied. Commercially, the more used topical creams which 
contains AKS have a composition at 5% by mass of API, that corresponds 
to 6,67% by mass of AKS [114,115]. Therefore, in order to obtain a solvent 
with a saturation point toward AKS equal to the therapeutic concentration, 
a solution of glycerol and water has been explored. The best composition 
is 45% water and 55% glycerol by mass. The saturation point of this 
solution is 71 mg·ml-1 that correspond to 62 mg·g-1 of AKS. Consequently, 
the API content is 4.8% by mass. In this case two different AKS saturated 
solution has been done. In a solution, 80 mg of OMS-AKS (27.5 % by 
mass) has been added under agitation. Every hour, for 4 times, 100 μl 
has been withdraw and substituted with the same amount of pure solvent. 
Figure 4.2 reports the measured concentration in the four withdraw for 
each sample. The saturated concentration is preserved as long as there 
is drug that can be solubilized from the OMS. In fact, 22 mg of drug where 
presents as reservoir and in the three subsequent dilution 21.3 mg where 
withdraw: 100 μl contains 7.1 mg of API. 
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Figure 4.2: AKS sustained release with 21.3 mg of API contained in OMS-AKS 
(a) and without reservoir (b).  
 
4.2 COMPOSITION, RHEOLOGICAL AND pH STABILITY OF AKS-OMS 
GEL 
 
As previously described an innovative topical semisolid formulation has 
been prepared and compared to a commercial formulation. All the results 
here presented are referred to the gel named AKS-OMS gel.  Among all 
the semisolid preparations, a hydrophilic gel was developed, consisting of 
a liquid phase within a polymeric matrix composed by a suitable gelling 
agent. Firstly, AKS was added in a solution of glycerol (45% by mass) and 
water (55% by mass) under magnetic stirring obtaining a saturated 
solution of the drug. When AKS was completely dissolved, 15% by mass 
OMS-AKS powder was added to the medium and then the liquid 
dispersion was purposely homogenized with a high shear homogenizer 
for 5 min at maximum velocity. Hydroxyethyl cellulose was selected as 
gelling agent, because it is primarily used in topical pharmaceutical 
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formulations and it is generally considered as an essentially non-toxic and 
non-irritant material [116]. With this purpose, 2% by mass of hydroxyethyl 
cellulose was added to the homogeneous dispersion and it was gently 
stirred for one hour at room temperature.  
The gel shows rheological characteristic of shear-thinning fluid. Over one 
month the viscosity at low shear rate is halved but preserve is 
pseudoplastic behaviour. The Farrow's constant was 3.4 n and remain the 
same over the month, going out of linearity only for low shear rate (3.9 n).  
During the same period, the pH oscillates from 4.75 to 5.0 without the 
addition of any correctors. It should be noted that this pH is equal to the 
pH of the commercial formulation.  
 
4.3 IN-VITRO RELEASE STUDIES 
 
Figure 4.3 reports the release curves obtained. In the first 100 minutes, 
AKS-OMS gel follows the commercial formulation. After, the commercial 
formulation release rate decrease since the AKS dissolved quantity is 
ending. In that moment, the OMS-AKS reservoir starts to make a 
difference in the AKS-OMS gel. Indeed, the release rate of AKS-OMS gel 
remains constant until 200-250 minutes. Finally, also the OMS-AKS 
reservoir end and the release rate decrease. 
The constant release rate in the first 100 minutes proves that the starting 
dissolved concentration of AKS inside AKS-OMS gel and commercial 
formulation is the same. The preservation of a constant release rate after 
100 minutes of AKS-OMS gel proves that the dissolved concentration of 
AKS is sustained to the therapeutics concentration until 200-250 minutes. 
These demonstrate the feasibility of this application as a method to reduce 
the number of applications during the day. 
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Figure 4.3: In-vitro release test of AKS-OMS gel (a) and the commercial 
formulation (b). Each point is the mean value of three different release tests. The 
error bars include the maximum variation obtained from all the different trials. 
 
4.4 IN-VITRO PERMEATION STUDIES 
 
In order to evaluate differences in permeation of the two semisolid 
formulation on a skin site, a slice of porcine ear skin has been mounted 
on the Franz cells (Figure 4.4). Until 100 minutes, as the release test, the 
permeated quantities are small and similar. After, the AKS permeated 
from AKS-OMS gel exceed the commercial formulation quantity. This is 
in agreement with the release studies that show the depletion of the 
commercial formulation after 100 minutes. Consequently, the permeation 
of AKS is influenced from the depletion of the commercial formulation. On 
the other hand, the constant concentration present in the AKS-OMS gel 
develop an increase in the permeated quantity. The complete permeation 
of AKS from the commercial formulation requires 24 h, while for AKS-
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OMS gel it exceeds 48 h. After 4 days, no more AKS permeation is 
observed. 
 
Figure 4.4: In-vitro permeation test of AKS-OMS gel (a) and the commercial 
formulation (b). On the left (I) the first 350 minutes; on the right (II) the 
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subsequent 168 h. Each point is the mean value of three different release tests. 
The error bars include the maximum variation obtained from all the different 
trials.  
These results show that a constant concentration over the skin site for a 
prolonged time extend and enhance the permeation of API. The first result 
was intended. On the other hand, the enhancement could produce an 
overtreatment, solvable reducing the saturation point of the vehicle. This 
solution leads to more improvement of the new semisolid formulation. 
Indeed, reducing the dissolved starting therapeutic concentration will 
increase directly the duration of the stored AKS. Secondly, the same 
antibiotic effect could be achieved with less dosage on the application site. 
 
4.5 TOPOLOGICAL INFORMATION ON OMS PERMEATION 
 
Numerous works study the possible permeation of OMS through the skin 
site of application [117–119]. To the best of our knowledge, none of these 
papers reports a direct permeation of particles greater than 10 nm. On the 
other hand, it is well labelled the possibility for these particles to enter skin 
pores and hair follicles, enhancing the drug release [117]. In order to 
observe the OMS-Skin interactions, during the permeation studies, 
different experiments were stopped at 6, 24, 48 and 72 h (Figure 4.5). 
Between 6 to 48 h, the OMS particles are in aggregate on the skin. These 
aggregates are formed during samples preparation for FESEM analysis. 
However, after 72h, OMS are dispersed in the first 200 μm of thickness 
and are hardly to be distinguished. Therefore, OMS-Skin interaction is 
weakly and a long period is required to OMS particles to stick to skin pores 
and hair follicles. 
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Figure 4.5: FESEM image of the In-vitro permeation test of AKS-OMS gel: 6, 
24, 48 and 72h. OMS particles in the form of aggregates are observable very 
bright in the upper left part of 6h (a), bright in the upper right of 24h (b), hardly 
visible in the upper part of 48h (c). Image (d) reports the OMS dispersion on the 
skin after 72h.  
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CHAPTER 5: CTZ-OMS GEL 
 
ABSTRACT 
 
Controlled drug delivery from Ordered Mesoporous Silica (OMS) 
platforms represents the possibility to achieve sustained or prolonged 
drug release in different administration routes widely used, from the oral 
to the parenteral one [93]. Nevertheless, exploring the literature it is quite 
evident that much research work have been addressed to investigate 
OMS nanoparticles as drug delivery system for the oral route, in particular 
for poorly-water soluble molecules, or for parenteral systems releasing 
active pharmaceutical ingredients after a triggered external stimuli 
[10,30,97,120]. To the best of our knowledge, only few papers have been 
published about the possibility to use silica-based mesoporous 
nanoparticles for topical application [121–126]. Skin is generally used as 
route of delivery for local and systemic drugs.  
This chapter presents the development and application of the new 
controlled release system with CTZ. The complete physicochemical 
characterization of the OMS incorporated with API has been totally 
described in the previous chapter. Subsequently, in this section are 
reported only the release tests of different saturated vehicle to ensure the 
effectiveness of the controlled system. Afterwards, the preparation and 
characterization of an innovative topical semisolid formulation for CTZ 
comparable to commercial formulations. Finally, sustained release of CTZ 
has been developed and outlined with vertical glass diffusion cells.  
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5.1 SUSTAINED RELEASE OF OMS-CTZ IN CTZ SATURATED 
SOLUTIONS 
 
In parallel with the sustained release test of AKS, also CTZ has been 
tested. For CTZ the typical topical creams are between 1 and 2,5% by 
mass of API content [65]. Therefore, a solution of 1,2-propandiol and water 
has been studied. The best conditions were with 85% 1,2-propandiol and 
15% water by mass. This solution has a saturation point of 25 mg·ml-1 that 
corresponds to 2,4% by mass of API. The same procedure used for AKS 
has been followed and in figure 5.1 are reported the measured 
concentration. The concentration decrease only after the complete 
solubilisation of the incorporated API. Each withdraw of 100 μl contains 
2.5 mg of API and the reservoir of OMS-CTZ was 7 mg (70 mg of OMS-
CTZ at 10%)  
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Figure 5.1: CTZ sustained release with 7 mg of API contained in OMS-CTZ (a) 
and without reservoir (b).  
 
5.2 COMPOSITION AND IN-VITRO RELEASE TEST 
 
A topical semisolid formulation has been prepared and compared to a 
commercial formulation. In this case the CTZ gel, named CTZ-OMS gel, 
is a hydrophobic semisolid preparation. It consists of 85% 1,2-propandiol 
and 15% of bidistilled water. When CTZ is dissolved, 10% by mass OMS-
CTZ powder was added to the medium. In this case MSU-H-CTZ-34 has 
been used. Then, the liquid dispersion was purposely homogenized with 
a high shear homogenizer for 5 min at maximum velocity.  As gelling agent 
hydroxyethyl cellulose was selected as gelling agent, 2% by mass. The 
gel shows rheological characteristic of shear-thinning fluid.  
Figure 5.2: In-vitro release test of CTZ-OMS gel (a) and the commercial 
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formulation (b). Each point is the mean value of three different release tests. The 
error bars include the maximum variation obtained from all the different trials.  
Figure 5.2 reports the in-vitro release curves obtained. In this case, for the 
first 2h, CTZ-OMS gel follows the commercial formulation. The 
commercial formulation release rate bends and stops around 5h from the 
start. On the other hand, CTZ-OMS gel continues almost linearly until 24h.  
The constant release rate in the first 2 hours verifies that the starting free 
concentration of CTZ inside CTZ-OMS gel and the commercial 
formulation is the same. The preservation of a constant release rate until 
5-6 hours proves the capability for CTZ-OMS gel of a sustained release 
to the therapeutics concentration. Unfortunately, the release rate seems 
to decrease gradually and not uniformly like the commercial formulation. 
Probably more tests should be done from 7 to 24 hours in order to control 
better the release profile of CTZ-OMS gel. 
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CONCLUSIONS 
 
In this PhD work Ordered Mesoporous Silica has been studied and used 
for a new controlled release technology for topical applications: starting 
from the physicochemical characterization to the development of real 
formulations.  
In the first chapter, has been shown the positive and negatives aspects of 
different incorporation techniques based on hydrophilicity/hydrophobicity 
of Clotrimazole and Amikacin Sulfate. This have been correlated with 
dissimilar type of OMS. 
With Clotrimazole a theoretical-experimental comparison between results 
has been done tackling phenomena like: mobility, solubility, 
bioavailability, etc. All the theoretical and experimental results were in line 
each other. 
Strong of this correlation the differences between types of OMS have 
been highlighted trying to explain the spatial assembly of drug inside the 
mesoporous channels of OMS in function of pore dimensions. 
Finally, the new controlled release technology has been discussed and 
demonstrated in its functionality for Clotrimazole and Amikacin Sulfate. 
Both systems have demonstrated double release time without leaving the 
therapeutic concentration. 
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